{
    "filename": "2020.03.03.962332.full.pdf",
    "content_type": "application/pdf",
    "file_size": 234038,
    "metadata": {
        "identifiers": {
            "doi": "10.1101/2020.03.03.962332",
            "url": "https://www.biorxiv.org/content/biorxiv/early/2020/03/03/2020.03.03.962332.full.pdf"
        },
        "title": "Multi-epitope vaccine design using an immunoinformatics approach for 2019 novel coronavirus in China (SARS-CoV-2)",
        "author": "Ye Feng, Min Qiu, Shengmei Zou, Yun Li, Kai Luo, Rongchang Chen, Yingqiang Sun, Kui Wang, Xinlei Zhuang, Shanshan Zhang, Shuqing Chen, Fan Mo",
        "date": 2020,
        "affiliations": [
            "Run Run Shaw Hospital, Zhejiang University School of Medicine, Hangzhou, China; 2",
            "Institute for Translational Medicine, Zhejiang University School of Medicine, Hangzhou, China; 3",
            "Hangzhou Neoantigen Therapeutics Co., Ltd., Hangzhou, China; 4",
            "Zhejiang Forest Resources Monitoring Center, Hangzhou, China;",
            "College of Pharmaceutical",
            "Sciences, Zhejiang University, Hangzhou, China;",
            "Zhejiang California International Nanosystems",
            "Institute, Zhejiang University, Hangzhou, China;",
            "Vancouver Prostate Centre, University of",
            "British Columbia, Vancouver, BC, Canada."
        ],
        "abstract": "A new coronavirus SARS-CoV-2, recently discovered in Wuhan, China, has caused over 74000 infection cases and 2000 deaths. Due to the rapidly growing cases and the unavailability of specific therapy, there is a desperate need for vaccines to combat the epidemic of SARS-CoV-2. In the present study, we performed an in silico approach based on the available virus genome to identify the antigenic B-cell epitopes and human-leukocyte-antigen (HLA) restricted T-cell epitopes. A total of 61 B-cell epitopes were initially identified, 19 of which with higher potential immunogenicity were used for vaccine design. 499 T-cell epitopes were predicted that showed affinity with the 34 most popular HLA alleles in Chinese population. Based on these epitopes, 30 vaccine candidates were designed and inspected against safety risks, including potential toxicity, human homologous, pharmaceutical peptides and bioactive peptides. Majority of vaccine peptides contained both B-cell and T-cell epitopes, which may interact with the most prevalent HLA alleles accounting for ~99% of Chinese population. Docking analysis showed stable hydrogen bonds of epitopes with their corresponding HLA alleles. In conclusion, these putative antigenic peptides may elicit the resistance response to the viral infection. In vitro and in vivo experiments are required to validate the effectiveness of these peptide vaccine.",
        "keywords": [
            "SARS-CoV-2",
            "epitope",
            "immunoinformatics",
            "vaccine"
        ],
        "references": "@article{almofti2018a,\n  author = {Almofti, Y.A. and Abd-elrahman, K.A. and Gassmallah, S.A.E. and Salih, M.A.},\n  date = {2018},\n  title = {Multi Epitopes 222 Vaccine Prediction against Severe Acute Respiratory Syndrome (SARS) Coronavirus Using 223 Immunoinformatics Approaches},\n  journal = {American Journal of Microbiological Research},\n  volume = {6},\n  pages = {94\u2013114},\n  language = {}\n}\n@article{babcock2004a,\n  author = {Babcock, G.J. and Esshaki, D.J. and Thomas, W.D. and Ambrosino, D.M.},\n  date = {2004},\n  title = {Amino acids 270 to 510 225 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction 226 with receptor},\n  journal = {J Virol},\n  volume = {78},\n  pages = {4552\u20134560},\n  language = {}\n}\n@article{benvenuto-a,\n  author = {},\n  journal = {The},\n  volume = {228},\n  title = {2019\u2010new coronavirus epidemic: evidence for virus evolution},\n  unmatched-journal = {Journal of Medical Virology.},\n  language = {}\n}\n@article{black2010a,\n  author = {Black, M. and Trent, A. and Tirrell, M. and Olive, C.},\n  date = {2010},\n  title = {Advances in the design and delivery of peptide 230 subunit vaccines with a focus on toll-like receptor agonists},\n  journal = {Expert review of vaccines},\n  volume = {9},\n  pages = {157\u2013173},\n  number = {231},\n  language = {}\n}\n@article{buchholz2004a,\n  author = {},\n  date = {2004},\n  title = {Contributions of the structural proteins of severe acute respiratory 234 syndrome coronavirus to protective immunity},\n  journal = {P Natl Acad Sci USA},\n  volume = {101},\n  pages = {9804\u20139809},\n  language = {}\n}\n@article{chen2007a,\n  author = {Chen, J. and Liu, H. and Yang, J. and Chou, K.-C.},\n  date = {2007},\n  title = {Prediction of linear B-cell epitopes using amino 236 acid pair antigenicity scale},\n  journal = {Amino acids},\n  volume = {33},\n  pages = {423\u2013428},\n  language = {}\n}\n@article{chen-a,\n  author = {Chen, Y. and Liu, Q. and Guo, D.},\n  title = {Emerging coronaviruses: genome structure, replication, and 238 pathogenesis},\n  journal = {Journal of Medical Virology},\n  language = {}\n}\n@misc{dong-a,\n  author = {},\n  title = {Genomic and 240 protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new 241 coronavirus which caused a pneumonia outbreak in Wuhan, China. bioRxiv},\n  language = {}\n}\n@article{fieser1987a,\n  author = {Fieser, T.M. and Tainer, J.A. and Geysen, H.M. and Houghten, R.A. and Lerner, R.A.},\n  date = {1987},\n  title = {Influence of 243 protein flexibility and peptide conformation on reactivity of monoclonal anti-peptide antibodies with a protein alpha-helix},\n  journal = {Proceedings of the National Academy of Sciences},\n  volume = {84},\n  pages = {8568\u20138572},\n  language = {}\n}\n@article{gorbalenya-a,\n  author = {Gorbalenya, A.E.},\n  title = {2020. <em>Severe acute respiratory syndrome-related coronavirus \u2013 The 246 species and its viruses, a statement of the Coronavirus Study Group},\n  journal = {bioRxiv},\n  volume = {247},\n  number = {2020},\n  language = {}\n}\n@article{gralinski-a,\n  author = {},\n  title = {Return of the Coronavirus: 2019-nCoV},\n  journal = {Viruses},\n  volume = {12},\n  number = {249 135},\n  language = {}\n}\n@article{he2005a,\n  author = {He, Y.X. and Lu, H. and Siddiqui, P. and Zhou, Y.S. and Jiang, S.B.},\n  date = {2005},\n  title = {Receptor-binding domain of 251 severe acute respiratory syndrome coronavirus spike protein contains multiple 252 conformation-dependent epitopes that induce highly potent neutralizing antibodies},\n  journal = {J Immunol},\n  volume = {253},\n  pages = {4908\u20134915},\n  number = {174},\n  language = {}\n}\n@misc{hoof2009a,\n  author = {Hoof, I. and Peters, B. and Sidney, J. and Pedersen, L.E. and Sette, A. and Lund, O. and Buus, S. and Nielsen, M.},\n  date = {2009}\n}\n@misc{huang2020a,\n  author = {Huang, C. and Wang, Y. and Li, X. and Ren, L. and Zhao, J. and Hu, Y. and Zhang, L. and Fan, G. and Xu, J. and Gu, X.},\n  date = {2020}\n}\n@misc{unknown-a,\n  title = {Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The 259 Lancet},\n  language = {}\n}\n@article{jespersen2017a,\n  author = {Jespersen, M.C. and Peters, B. and Nielsen, M. and Marcatili, P.},\n  date = {2017},\n  title = {BepiPred- 2.0: improving 261 sequence-based B-cell epitope prediction using conformational epitopes},\n  journal = {Nucleic acids},\n  volume = {262},\n  pages = {24\u201329},\n  number = {45},\n  language = {}\n}\n@misc{jiayuan-a,\n  author = {},\n  title = {Bioinformatics analysis of the Wuhan 2019 human coronavirus genome},\n  language = {}\n}\n@misc{joseph-a,\n  author = {},\n  title = {Nowcasting and forecasting the potential 266 domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a 267 modelling study. The Lancet},\n  language = {}\n}\n@misc{lamiable2016a,\n  author = {Lamiable, A. and Thevenet, P. and Rey, J. and Vavrusa, M. and Derreumaux, P. and Tuffery, P.},\n  date = {2016}\n}\n@article{lerner1981a,\n  author = {Lerner, R.A. and Green, N. and Alexander, H. and Liu, F.-T. and Sutcliffe, J.G. and Shinnick, T.},\n  journal = {M},\n  date = {1981}\n}\n@article{unknown-b,\n  title = {the},\n  journal = {National Academy of Sciences},\n  volume = {78},\n  pages = {3403\u20133407},\n  language = {},\n  organization = {Proceedings of}\n}\n@misc{lu-a,\n  author = {},\n  volume = {277},\n  title = {2020. Genomic characterisation and epidemiology 279 of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet},\n  unmatched-author = {Wang, J., Lin, Y., Yuan, J., Xie, Z., Ma, J., Liu, W. J., Wang, D., Xu, W., Holmes, E. C., Gao, 278 G. F., Wu, G., Chen, W., Shi, W., Tan, W.,},\n  language = {}\n}\n@misc{organization-a,\n  author = {Organization, W. H., 2020},\n  title = {Surveillance case definitions for human infection with novel 281 coronavirus (nCoV): interim guidance v1},\n  date = {January},\n  editor = {},\n  unknown = {World 282 Health Organization, Geneva},\n  language = {}\n}\n@article{perlman-a,\n  author = {Perlman, S., 2020},\n  title = {Another Decade, Another Coronavirus},\n  journal = {New England Journal of Medicine},\n  language = {}\n}\n@article{purcell2007a,\n  author = {Purcell, A.W. and McCluskey, J. and Rossjohn, J.},\n  date = {2007},\n  title = {More than one reason to rethink the use of 285 peptides in vaccine design},\n  journal = {Nat Rev Drug Discov},\n  volume = {6},\n  pages = {404\u2013414},\n  language = {}\n}\n@article{saif1993a,\n  author = {Saif, L.J.},\n  date = {1993},\n  title = {Coronavirus Immunogens},\n  journal = {Vet Microbiol},\n  volume = {37},\n  pages = {285\u2013297},\n  language = {}\n}\n@article{sesardic1993a,\n  author = {Sesardic, D.},\n  date = {1993},\n  title = {Synthetic peptide vaccines},\n  journal = {Journal of medical microbiology},\n  volume = {39},\n  pages = {241\u2013242},\n  language = {}\n}\n@article{skwarczynski2016a,\n  author = {Skwarczynski, M. and Toth, I.},\n  date = {2016},\n  title = {Peptide-based synthetic vaccines},\n  journal = {Chemical science},\n  volume = {7},\n  pages = {842\u2013854},\n  number = {289},\n  language = {}\n}\n@misc{tian2020a,\n  author = {Tian, X. and Li, C. and Huang, A. and Xia, S. and Lu, S. and Shi, Z. and Lu, L. and Jiang, S. and Yang, Z. and Wu, Y.},\n  date = {2020}\n}\n@misc{unknown-c,\n  title = {Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human 292 monoclonal antibody. bioRxiv},\n  language = {}\n}\n@misc{vita2015a,\n  author = {},\n  date = {2015},\n  title = {The immune epitope database (IEDB) 3.0},\n  language = {}\n}\n@article{waterhouse2018a,\n  author = {Waterhouse, A. and Bertoni, M. and Bienert, S. and Studer, G. and Tauriello, G. and Gumienny, R. and Heer, F.},\n  volume = \"T.,\" # \"SWISS-MODEL: 298\" # \"46,\",\n  pages = \"297\" # \"W296-W303.\",\n  date = {2018},\n  title = {homology modelling of protein structures and complexes},\n  journal = {Nucleic Acids Res},\n  unmatched-author = {de Beer, T. A. P., Rempfer, C., Bordoli, L., Lepore, R., Schwede, T.,},\n  unmatched-volume = {SWISS-MODEL: 298 46,},\n  unmatched-pages = {W296-W303.},\n  language = {}\n}\n@article{wrapp-a,\n  author = {},\n  title = {Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion 301 Conformation},\n  journal = {bioRxiv},\n  volume = {2020},\n  number = {2002},\n  language = {}\n}\n@article{xu2018a,\n  author = {Xu, X. and Yan, C. and Zou, X.},\n  date = {2018},\n  title = {MDockPeP: An ab-initio protein-peptide docking server},\n  journal = {Journal},\n  volume = {303},\n  unknown = {of computational chemistry 39},\n  pages = {2409\u20132413},\n  language = {}\n}\n@misc{zhao-a,\n  author = {Zhao, Y. and Zhao, Z. and Wang, Y. and Zhou, Y. and Ma, Y. and Zuo, W.},\n  title = {2020. Single-cell RNA expression 305 profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv},\n  language = {}\n}\n@misc{zhou-a,\n  author = {},\n  title = {Discovery of a novel coronavirus associated with the recent pneumonia 308 outbreak in humans and its potential bat origin. bioRxiv},\n  language = {}\n}\n",
        "links": [
            "https://github.com/schrodinger/pymol-open-source"
        ],
        "emails": [
            "chenshuqing@zju.edu.cn",
            "mofan_hz@163.com"
        ],
        "references_ris": "TY  - JOUR\nAU  - Almofti, Y.A.\nAU  - Abd-elrahman, K.A.\nAU  - Gassmallah, S.A.E.\nAU  - Salih, M.A.\nPY  - 2018\nDA  - 2018\nTI  - Multi Epitopes 222 Vaccine Prediction against Severe Acute Respiratory Syndrome (SARS) Coronavirus Using 223 Immunoinformatics Approaches\nT2  - American Journal of Microbiological Research\nVL  - 6\nSP  - 94\nEP  - 114\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Babcock, G.J.\nAU  - Esshaki, D.J.\nAU  - Thomas, W.D.\nAU  - Ambrosino, D.M.\nPY  - 2004\nDA  - 2004\nTI  - Amino acids 270 to 510 225 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction 226 with receptor\nT2  - J Virol\nVL  - 78\nSP  - 4552\nEP  - 4560\nLA  - \nER  - \n\nTY  - JOUR\nT2  - The\nVL  - 228\nTI  - 2019\u2010new coronavirus epidemic: evidence for virus evolution\nC1  - Journal of Medical Virology.\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Black, M.\nAU  - Trent, A.\nAU  - Tirrell, M.\nAU  - Olive, C.\nPY  - 2010\nDA  - 2010\nTI  - Advances in the design and delivery of peptide 230 subunit vaccines with a focus on toll-like receptor agonists\nT2  - Expert review of vaccines\nVL  - 9\nSP  - 157\nEP  - 173\nIS  - 231\nLA  - \nER  - \n\nTY  - JOUR\nPY  - 2004\nDA  - 2004\nTI  - Contributions of the structural proteins of severe acute respiratory 234 syndrome coronavirus to protective immunity\nT2  - P Natl Acad Sci USA\nVL  - 101\nSP  - 9804\nEP  - 9809\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Chen, J.\nAU  - Liu, H.\nAU  - Yang, J.\nAU  - Chou, K.-C.\nPY  - 2007\nDA  - 2007\nTI  - Prediction of linear B-cell epitopes using amino 236 acid pair antigenicity scale\nT2  - Amino acids\nVL  - 33\nSP  - 423\nEP  - 428\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Chen, Y.\nAU  - Liu, Q.\nAU  - Guo, D.\nTI  - Emerging coronaviruses: genome structure, replication, and 238 pathogenesis\nT2  - Journal of Medical Virology\nLA  - \nER  - \n\nTY  - GEN\nTI  - Genomic and 240 protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new 241 coronavirus which caused a pneumonia outbreak in Wuhan, China. bioRxiv\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Fieser, T.M.\nAU  - Tainer, J.A.\nAU  - Geysen, H.M.\nAU  - Houghten, R.A.\nAU  - Lerner, R.A.\nPY  - 1987\nDA  - 1987\nTI  - Influence of 243 protein flexibility and peptide conformation on reactivity of monoclonal anti-peptide antibodies with a protein alpha-helix\nT2  - Proceedings of the National Academy of Sciences\nVL  - 84\nSP  - 8568\nEP  - 8572\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Gorbalenya, A.E.\nTI  - 2020. <em>Severe acute respiratory syndrome-related coronavirus \u2013 The 246 species and its viruses, a statement of the Coronavirus Study Group\nT2  - bioRxiv\nVL  - 247\nIS  - 2020\nLA  - \nER  - \n\nTY  - JOUR\nTI  - Return of the Coronavirus: 2019-nCoV\nT2  - Viruses\nVL  - 12\nIS  - 249 135\nLA  - \nER  - \n\nTY  - JOUR\nAU  - He, Y.X.\nAU  - Lu, H.\nAU  - Siddiqui, P.\nAU  - Zhou, Y.S.\nAU  - Jiang, S.B.\nPY  - 2005\nDA  - 2005\nTI  - Receptor-binding domain of 251 severe acute respiratory syndrome coronavirus spike protein contains multiple 252 conformation-dependent epitopes that induce highly potent neutralizing antibodies\nT2  - J Immunol\nVL  - 253\nSP  - 4908\nEP  - 4915\nIS  - 174\nLA  - \nER  - \n\nTY  - GEN\nAU  - Hoof, I.\nAU  - Peters, B.\nAU  - Sidney, J.\nAU  - Pedersen, L.E.\nAU  - Sette, A.\nAU  - Lund, O.\nAU  - Buus, S.\nAU  - Nielsen, M.\nPY  - 2009\nDA  - 2009\nER  - \n\nTY  - GEN\nAU  - Huang, C.\nAU  - Wang, Y.\nAU  - Li, X.\nAU  - Ren, L.\nAU  - Zhao, J.\nAU  - Hu, Y.\nAU  - Zhang, L.\nAU  - Fan, G.\nAU  - Xu, J.\nAU  - Gu, X.\nPY  - 2020\nDA  - 2020\nER  - \n\nTY  - GEN\nTI  - Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The 259 Lancet\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Jespersen, M.C.\nAU  - Peters, B.\nAU  - Nielsen, M.\nAU  - Marcatili, P.\nPY  - 2017\nDA  - 2017\nTI  - BepiPred- 2.0: improving 261 sequence-based B-cell epitope prediction using conformational epitopes\nT2  - Nucleic acids\nVL  - 262\nSP  - 24\nEP  - 29\nIS  - 45\nLA  - \nER  - \n\nTY  - GEN\nTI  - Bioinformatics analysis of the Wuhan 2019 human coronavirus genome\nLA  - \nER  - \n\nTY  - GEN\nTI  - Nowcasting and forecasting the potential 266 domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a 267 modelling study. The Lancet\nLA  - \nER  - \n\nTY  - GEN\nAU  - Lamiable, A.\nAU  - Thevenet, P.\nAU  - Rey, J.\nAU  - Vavrusa, M.\nAU  - Derreumaux, P.\nAU  - Tuffery, P.\nPY  - 2016\nDA  - 2016\nER  - \n\nTY  - JOUR\nAU  - Lerner, R.A.\nAU  - Green, N.\nAU  - Alexander, H.\nAU  - Liu, F.-T.\nAU  - Sutcliffe, J.G.\nAU  - Shinnick, T.\nT2  - M\nPY  - 1981\nDA  - 1981\nER  - \n\nTY  - JOUR\nTI  - the\nT2  - National Academy of Sciences\nVL  - 78\nSP  - 3403\nEP  - 3407\nLA  - \nC1  - Proceedings of\nER  - \n\nTY  - GEN\nVL  - 277\nTI  - 2020. Genomic characterisation and epidemiology 279 of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet\nC1  - Wang, J., Lin, Y., Yuan, J., Xie, Z., Ma, J., Liu, W. J., Wang, D., Xu, W., Holmes, E. C., Gao, 278 G. F., Wu, G., Chen, W., Shi, W., Tan, W.,\nLA  - \nER  - \n\nTY  - GEN\nAU  - Organization, W. H., 2020\nTI  - Surveillance case definitions for human infection with novel 281 coronavirus (nCoV): interim guidance v1\nPY  - January\nDA  - January\nC1  - World 282 Health Organization, Geneva\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Perlman, S., 2020\nTI  - Another Decade, Another Coronavirus\nT2  - New England Journal of Medicine\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Purcell, A.W.\nAU  - McCluskey, J.\nAU  - Rossjohn, J.\nPY  - 2007\nDA  - 2007\nTI  - More than one reason to rethink the use of 285 peptides in vaccine design\nT2  - Nat Rev Drug Discov\nVL  - 6\nSP  - 404\nEP  - 414\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Saif, L.J.\nPY  - 1993\nDA  - 1993\nTI  - Coronavirus Immunogens\nT2  - Vet Microbiol\nVL  - 37\nSP  - 285\nEP  - 297\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Sesardic, D.\nPY  - 1993\nDA  - 1993\nTI  - Synthetic peptide vaccines\nT2  - Journal of medical microbiology\nVL  - 39\nSP  - 241\nEP  - 242\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Skwarczynski, M.\nAU  - Toth, I.\nPY  - 2016\nDA  - 2016\nTI  - Peptide-based synthetic vaccines\nT2  - Chemical science\nVL  - 7\nSP  - 842\nEP  - 854\nIS  - 289\nLA  - \nER  - \n\nTY  - GEN\nAU  - Tian, X.\nAU  - Li, C.\nAU  - Huang, A.\nAU  - Xia, S.\nAU  - Lu, S.\nAU  - Shi, Z.\nAU  - Lu, L.\nAU  - Jiang, S.\nAU  - Yang, Z.\nAU  - Wu, Y.\nPY  - 2020\nDA  - 2020\nER  - \n\nTY  - GEN\nTI  - Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human 292 monoclonal antibody. bioRxiv\nLA  - \nER  - \n\nTY  - GEN\nPY  - 2015\nDA  - 2015\nTI  - The immune epitope database (IEDB) 3.0\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Waterhouse, A.\nAU  - Bertoni, M.\nAU  - Bienert, S.\nAU  - Studer, G.\nAU  - Tauriello, G.\nAU  - Gumienny, R.\nAU  - Heer, F.\nVL  - \"T.,\" # \"SWISS-MODEL: 298\" # \"46,\"\nSP  - \"297\" # \"W296\nEP  - W303.\"\nPY  - 2018\nDA  - 2018\nTI  - homology modelling of protein structures and complexes\nT2  - Nucleic Acids Res\nC1  - de Beer, T. A. P., Rempfer, C., Bordoli, L., Lepore, R., Schwede, T.,\nC1  - SWISS-MODEL: 298 46,\nC1  - W296-W303.\nLA  - \nER  - \n\nTY  - JOUR\nTI  - Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion 301 Conformation\nT2  - bioRxiv\nVL  - 2020\nIS  - 2002\nLA  - \nER  - \n\nTY  - JOUR\nAU  - Xu, X.\nAU  - Yan, C.\nAU  - Zou, X.\nPY  - 2018\nDA  - 2018\nTI  - MDockPeP: An ab-initio protein-peptide docking server\nT2  - Journal\nVL  - 303\nC1  - of computational chemistry 39\nSP  - 2409\nEP  - 2413\nLA  - \nER  - \n\nTY  - GEN\nAU  - Zhao, Y.\nAU  - Zhao, Z.\nAU  - Wang, Y.\nAU  - Zhou, Y.\nAU  - Ma, Y.\nAU  - Zuo, W.\nTI  - 2020. Single-cell RNA expression 305 profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv\nLA  - \nER  - \n\nTY  - GEN\nTI  - Discovery of a novel coronavirus associated with the recent pneumonia 308 outbreak in humans and its potential bat origin. bioRxiv\nLA  - \nER  - \n\n",
        "author_conclusions": [],
        "table_captions": [
            {
                "id": "1",
                "caption": "B-cell epitope candidates"
            },
            {
                "id": "2",
                "caption": "Distribution of T-cell epitopes among three structural proteins"
            },
            {
                "id": "3",
                "caption": "Candidate vaccine peptides"
            },
            {
                "id": "4",
                "caption": "Docking results for T-cell epitope P25 and P27 against three HLA types"
            }
        ],
        "figure_captions": [
            {
                "id": "1",
                "caption": "Distribution of B-cell and T-cell epitopes. The outermost circle (light blue) stands for the 314 T-cell epitope count. The 2rd outer circle stands for Emini (in red) and Kolaskar (in green) score 315 used to evaluate the B-cell epitopes. The 3rd circle marked the name of the viral proteins. The 316 4th-6th circles stands for HLA-A (in blue), HLA-B (in green), and HLA-C (in yellow) scores; the 317 points closer to the center indicates a lower score"
            },
            {
                "id": "2",
                "caption": "Locations of the recognized B cell epitopes on the viral spike protein (a), envelop protein 320 (b) and membrane protein (c). The transparent cartoon models display the predicted 3D structure; 321 the colorful balls marks the position of the recognized epitopes"
            },
            {
                "id": "3",
                "caption": "Interaction between the predicted peptides (by yellow sticks) and different HLA alleles (by 324 green cartoons). Amino acids were labeled adjacent to the contact sites. Epitope"
            }
        ],
        "tables_url": "https://scholarcy.nyc3.digitaloceanspaces.com/tables/docker-test/2020.03.03.962332.full.xlsx",
        "figure_urls": [
            "https://scholarcy.nyc3.digitaloceanspaces.com/images/docker-test/2020.03.03.962332.full/img-000.png"
        ]
    },
    "sections": {
        "introduction": [
            "Since December 2019, Wuhan City, Hubei Province, China has become the center of an outbreak of viral lung infections caused by a new type of coronavirus, SARS-CoV-2 (previously named<br/><br/>2019-nCoV by the World Health Organization) (<a class=\"ref-link\" id=\"cGorbalenya_2020_a\" href=\"#rGorbalenya_2020_a\">Gorbalenya, 2020</a>; Joseph T Wu*, 2020; Organization, 2020; <a class=\"ref-link\" id=\"cPerlman_2020_a\" href=\"#rPerlman_2020_a\">Perlman, 2020</a>).The outbreak has so far infected over 74000 patients, and has spread to approximately 30 countries/regions worldwide. Comparisons of the genome sequences of SARS-CoV-2 with other virus has shown 79.5% and 96% similarities at nucleotide level to<br/><br/>SARS-CoV and bat coronaviruses, respectively (Zhou et al, 2020), which suggested its probable origin in bats (Benvenuto et al, 2020). The main clinical manifestations of SARS-CoV-2 patients are fever (\u226538oC), dry cough, low or normal peripheral white blood cell count, and low lymphocyte count, known as novel coronavirus-infected pneumonia (NCIP) or coronavirus disease 2019 (COVID19) (<a class=\"ref-link\" id=\"cHuang_et+al_2020_a\" href=\"#rHuang_et+al_2020_a\">Huang et al, 2020</a>).<br/><br/>Currently, there is no approved therapeutics or vaccines available for the treatment of<br/><br/>COVID19 (Chen et al.). Due to lack of anti-viral drugs or vaccines, control measures have been relying on the rapid detection and isolation of symptomatic cases (Chen et al.). In this context, a safe and efficacious vaccine is urgently required. Traditional approaches for developing vaccines waste much time in isolating, inactivating and injecting the microorganisms (or portions of them) that cause disease. Fortunately, computation-based method enable us to start from analysis of viral genome, without the need to grow pathogens and therefore speeding up the entire process."
        ],
        "methods": [
            "2.1. Data retrieval<br/><br/>The genome sequence of SARS-CoV-2 isolate Wuhan-Hu-1 was retrieved from the NCBI database under the accession number MN908947. Gene and protein sequences were acquired according to the annotation. In particular, the RBD region for the spike protein was referred to as the fragment from 347 to 520 amino acid (aa) (Lu et al, 2020).<br/><br/>2.2. B-cell epitope prediction<br/><br/>The online tool in IEDB (Immune-Epitope-Database And Analysis-Resource) was used for the analysis of the conserved regions of the candidate epitopes (Vita et al, 2015). Prediction of linear"
        ],
        "data_availability": [
            "3. Results and Discussion 3.1. Prediction of B-cell epitopes During the immune response against viral infection, B-cell takes in viral epitopes to recognize viruses and activates defense responses. Recognition of B-cell epitopes depends on antigenicity, accessibility of surface and predictions of linear epitope (<a class=\"ref-link\" id=\"cFieser_et+al_1987_a\" href=\"#rFieser_et+al_1987_a\">Fieser et al, 1987</a>). A total of 61 B-cell epitopes were predicted, which seemed preferentially located within certain regions of each gene (Figure 1; Figure 2; Table S1). Only 19 epitopes were exposed on the surface of the virion and had a high antigenicity score, indicating their potentials in initiating immune response. Therefore, they were considered to be promising vaccine candidates against B-cells. Among the 19 epitopes, 17 were longer than14 residues and located in the spike protein that contained RBD and functioned in host cell binding (Table 1). The average Emini score for the 19 epitopes was 2.744, and the average for Kolaskar (antigenicity) score was 1.015. Two epitopes were located within the RBD region, while the one with the highest Kolaskar score (1.059), 1052-FPQSAPH-1058, was located at position 1052aa of the spike protein."
        ],
        "conclusions": [
            "Vaccine design using an in silico prediction method is highly appreciated as it selects specific epitopes in proteins than conventional methods. In the present study, this reverse vaccinology approach was adopted to identify surface-exposed peptides, instead of targeting the whole pathogen which is obviously less efficient and effective. Immunogenic regions of antigenic epitopes of all proteins encoded by SARS-CoV-2 were screened to identify potential vaccine candidates. As a result, 17 vaccine peptides involving both T-cell epitopes and B-cell epitopes as well as 13 vaccine peptides involving T-cell epitopes only were successfully designed. These multi-epitope vaccines provided excellent candidates for the development of vaccines against<br/><br/>SARS-CoV-2. Various formulation of vaccine can be rapidly manufactured, such as peptide, DNA and mRNA. However in vitro and in vivo trials are required to achieve the effectiveness of these vaccine peptides."
        ],
        "acknowledgements": [
            "This work was supported by Zhejiang Provincial Natural Science Foundation of China.<br/><br/>Author contributions<br/><br/>SC and FM conceived and designed the project. MQ, SZ, KL, RC, YS, KW, XZ and SZ analysed the data. YF and YL wrote the initial draft. All authors revised and approved the final manuscript."
        ],
        "funding": [
            "This work was supported by Zhejiang Provincial Natural Science Foundation of China. Author contributions SC and FM conceived and designed the project"
        ],
        "disclosures": [
            "Declarations of interest: none"
        ],
        "supplementary_references": {
            "supplementary_data_references": [],
            "supplementary_figure_references": [
                "Table S1",
                "Table S2",
                "Table S3"
            ]
        }
    },
    "structured_content": {
        "Abstract": [
            "A new coronavirus SARS-CoV-2, recently discovered in Wuhan, China, has caused over 74000 infection cases and 2000 deaths. Due to the rapidly growing cases and the unavailability of specific therapy, there is a desperate need for vaccines to combat the epidemic of SARS-CoV-2. In the present study, we performed an in silico approach based on the available virus genome to identify the antigenic B-cell epitopes and human-leukocyte-antigen (HLA) restricted T-cell epitopes. A total of 61 B-cell epitopes were initially identified, 19 of which with higher potential immunogenicity were used for vaccine design. 499 T-cell epitopes were predicted that showed affinity with the 34 most popular HLA alleles in Chinese population. Based on these epitopes, 30 vaccine candidates were designed and inspected against safety risks, including potential toxicity, human homologous, pharmaceutical peptides and bioactive peptides. Majority of vaccine peptides contained both B-cell and T-cell epitopes, which may interact with the most prevalent HLA alleles accounting for ~99% of Chinese population. Docking analysis showed stable hydrogen bonds of epitopes with their corresponding HLA alleles. In conclusion, these putative antigenic peptides may elicit the resistance response to the viral infection. In vitro and in vivo experiments are required to validate the effectiveness of these peptide vaccine."
        ],
        "1. Introduction": [
            "Since December 2019, Wuhan City, Hubei Province, China has become the center of an outbreak of viral lung infections caused by a new type of coronavirus, SARS-CoV-2 (previously named",
            "2019-nCoV by the World Health Organization) (<a class=\"ref-link\" id=\"cGorbalenya_2020_a\" href=\"#rGorbalenya_2020_a\">Gorbalenya, 2020</a>; Joseph T Wu*, 2020; Organization, 2020; <a class=\"ref-link\" id=\"cPerlman_2020_a\" href=\"#rPerlman_2020_a\">Perlman, 2020</a>).The outbreak has so far infected over 74000 patients, and has spread to approximately 30 countries/regions worldwide. Comparisons of the genome sequences of SARS-CoV-2 with other virus has shown 79.5% and 96% similarities at nucleotide level to",
            "SARS-CoV and bat coronaviruses, respectively (Zhou et al, 2020), which suggested its probable origin in bats (Benvenuto et al, 2020). The main clinical manifestations of SARS-CoV-2 patients are fever (\u226538oC), dry cough, low or normal peripheral white blood cell count, and low lymphocyte count, known as novel coronavirus-infected pneumonia (NCIP) or coronavirus disease 2019 (COVID19) (<a class=\"ref-link\" id=\"cHuang_et+al_2020_a\" href=\"#rHuang_et+al_2020_a\">Huang et al, 2020</a>).",
            "Currently, there is no approved therapeutics or vaccines available for the treatment of",
            "COVID19 (Chen et al.). Due to lack of anti-viral drugs or vaccines, control measures have been relying on the rapid detection and isolation of symptomatic cases (Chen et al.). In this context, a safe and efficacious vaccine is urgently required. Traditional approaches for developing vaccines waste much time in isolating, inactivating and injecting the microorganisms (or portions of them) that cause disease. Fortunately, computation-based method enable us to start from analysis of viral genome, without the need to grow pathogens and therefore speeding up the entire process.",
            "Complete genome sequencing of SARS-CoV-2 has finished and paved the way for the vaccine development (Chen et al.). The genome of SARS-CoV-2 encodes the spike protein, the membrane protein, the envelope protein, the nucleocapsid protein and a few replication and transcription-related enzymes. Given the lack of repairing mechanism of RNA virus replicase complex, mutations are prone to occur during virus replication. The 4% nucleotide difference of the virus isolated from Rhinolophus to that from human suggests that SARS-CoV-2 mutates rapidly to achieve the host conversion (Jiayuan Chen, 2020). Like SARS-CoV, SARS-CoV-2 uses its receptor binding domain (RBD) on the spike protein to bind to the host\u2019s angiotensin-converting enzyme 2 (ACE2) (Chen et al.; Dong et al, 2020; <a class=\"ref-link\" id=\"cTian_et+al_2020_a\" href=\"#rTian_et+al_2020_a\">Tian et al, 2020</a>; Zhou et al, 2020). In terms of binding capacity, the RBD of SARS-CoV-2 is much stronger than",
            "SARS-CoV and is considered to be between HKU3-4 which cannot bind to ACE2 receptor and rSHC014 which presents the largest binding energy (Gralinski and Menachery, 2020; Wrapp et al., 2020; <a class=\"ref-link\" id=\"cZhao_et+al_2020_a\" href=\"#rZhao_et+al_2020_a\">Zhao et al, 2020</a>). Consequently, the SARS-CoV-2 vaccine can be developed targeting the structural proteins, and in particular, the RBD region, following the strategy for the SARS-CoV vaccine development (<a class=\"ref-link\" id=\"cBabcock_et+al_2004_a\" href=\"#rBabcock_et+al_2004_a\">Babcock et al, 2004</a>; Buchholz et al, 2004; <a class=\"ref-link\" id=\"cHe_et+al_2005_a\" href=\"#rHe_et+al_2005_a\">He et al, 2005</a>; <a class=\"ref-link\" id=\"cSaif_1993_a\" href=\"#rSaif_1993_a\">Saif, 1993</a>; <a class=\"ref-link\" id=\"cTian_et+al_2020_a\" href=\"#rTian_et+al_2020_a\">Tian et al, 2020</a>).",
            "An ideal vaccine may contain both B-cell epitopes and T-cell epitopes, with combination of which vaccine is able to either induce specific humoral or cellular immune against pathogens efficiently (<a class=\"ref-link\" id=\"cPurcell_et+al_2007_a\" href=\"#rPurcell_et+al_2007_a\">Purcell et al, 2007</a>). Since the development of a peptide vaccine against the virus causing foot-and-mouth disease (Adam et al, 1978), the establishment of peptide synthesis method by Lerner et al (<a class=\"ref-link\" id=\"cLerner_et+al_1981_a\" href=\"#rLerner_et+al_1981_a\">Lerner et al, 1981</a>), along with the advent of a peptide vaccine design combining T-cell and B-cell epitopes, has accelerated the vaccine development. In the present study, we followed this in silico approach to identify the potential B-cell and T-cell epitope(s) from the spike, envelope and membrane proteins that could be used as promising vaccines against",
            "SARS-CoV-2."
        ],
        "2. Materials and Methods": [],
        "2.1. Data retrieval": [
            "The genome sequence of SARS-CoV-2 isolate Wuhan-Hu-1 was retrieved from the NCBI database under the accession number MN908947. Gene and protein sequences were acquired according to the annotation. In particular, the RBD region for the spike protein was referred to as the fragment from 347 to 520 amino acid (aa) (Lu et al, 2020)."
        ],
        "2.2. B-cell epitope prediction": [
            "The online tool in IEDB (Immune-Epitope-Database And Analysis-Resource) was used for the analysis of the conserved regions of the candidate epitopes (Vita et al, 2015). Prediction of linear",
            "B-cell epitopes was performed through Bepipred software (<a class=\"ref-link\" id=\"cJespersen_et+al_2017_a\" href=\"#rJespersen_et+al_2017_a\">Jespersen et al, 2017</a>). The antigenic sites were determined with Kolaskar method (<a class=\"ref-link\" id=\"cChen_et+al_2007_a\" href=\"#rChen_et+al_2007_a\">Chen et al, 2007</a>). The surface accessible epitopes were predicted by Emini tool (<a class=\"ref-link\" id=\"cAlmofti_et+al_2018_a\" href=\"#rAlmofti_et+al_2018_a\">Almofti et al, 2018</a>)."
        ],
        "2.3. T-cell epitope prediction": [
            "The sequences of structural proteins were split into small fragments with a length of 9aa; their binding affinity with the 34 most prevalent HLA alleles (>1% in the Chinese population according to data obtained from the website for China Marrow Donor Program (CMDP)) was predicted using netMHCpan (<a class=\"ref-link\" id=\"cHoof_et+al_2009_a\" href=\"#rHoof_et+al_2009_a\">Hoof et al, 2009</a>) and our in-house prediction software iNeo-Pred, respectively. iNeo-Pred was trained on a large immune-peptide dataset, and achieved a better performance in predicting binding affinity of epitopes to specific HLA alleles. Only the epitopes predicted by both tools were selected. Next, for each epitope, a HLA score was calculated based on the frequencies of binding HLA alleles in Chinese population, which will be used as metrics to select better candidates for downstream analysis."
        ],
        "2.4. Vaccine peptide design": [
            "The vaccine peptides were designed by our in-house tool iNeo-Design. First, the selected B-cell epitopes and their adjacent T-cell epitopes were bridged to form candidate peptides with length no more than 30aa. Meanwhile, to facilitate the peptide synthesis, vaccine peptide sequences were optimized based on their hydrophobicity and acidity. To minimize the safety risk, peptides that contained toxicity potential, human homologous region (full-length matches and identity > 95%), or bioactive peptide were discarded.",
            "Besides the vaccine peptides containing both B-cell epitopes and T-cell epitopes, iNeo-Design also utilized all predicted T-cell epitopes to generate T-cell epitopes-only vaccine peptides. For each vaccine candidate, the epitope counts and HLA score reflecting the population coverage were calculated. Vaccine candidates with the higher epitope counts and HLA score were considered to be preferable for the downstream analysis."
        ],
        "2.5. Structural analysis": [
            "HLA molecules (<a class=\"ref-link\" id=\"cWaterhouse_et+al_2018_a\" href=\"#rWaterhouse_et+al_2018_a\">Waterhouse et al, 2018</a>). The online server PEP_FOLD was used to predict",
            "T-cell epitopes\u2019 structures (<a class=\"ref-link\" id=\"cLamiable_et+al_2016_a\" href=\"#rLamiable_et+al_2016_a\">Lamiable et al, 2016</a>). To display the interaction between T-cell epitopes and HLA molecules, T-cell epitope models were docked to HLA molecules using",
            "MDockPep (<a class=\"ref-link\" id=\"cXu_et+al_2018_a\" href=\"#rXu_et+al_2018_a\">Xu et al, 2018</a>). All predicted structures or models were decorated and displayed by the open source version of pymol program (https://github.com/schrodinger/pymol-open-source).",
            "N/A."
        ],
        "Data availability": [],
        "3. Results and Discussion": [],
        "3.1. Prediction of B-cell epitopes": [
            "During the immune response against viral infection, B-cell takes in viral epitopes to recognize viruses and activates defense responses. Recognition of B-cell epitopes depends on antigenicity, accessibility of surface and predictions of linear epitope (<a class=\"ref-link\" id=\"cFieser_et+al_1987_a\" href=\"#rFieser_et+al_1987_a\">Fieser et al, 1987</a>). A total of 61 B-cell epitopes were predicted, which seemed preferentially located within certain regions of each gene (Figure 1; Figure 2; Table S1). Only 19 epitopes were exposed on the surface of the virion and had a high antigenicity score, indicating their potentials in initiating immune response. Therefore, they were considered to be promising vaccine candidates against B-cells. Among the 19 epitopes, 17 were longer than14 residues and located in the spike protein that contained RBD and functioned in host cell binding (Table 1). The average Emini score for the 19 epitopes was 2.744, and the average for Kolaskar (antigenicity) score was 1.015. Two epitopes were located within the RBD region, while the one with the highest Kolaskar score (1.059), 1052-FPQSAPH-1058, was located at position 1052aa of the spike protein."
        ],
        "3.2. Prediction of T-cell epitopes": [
            "The immune response of T-cell is considered as a long lasting response compared to B-cell where the antigen might easily escape the antibody memory response (<a class=\"ref-link\" id=\"cBlack_et+al_2010_a\" href=\"#rBlack_et+al_2010_a\">Black et al, 2010</a>). Moreover, the",
            "CD8+ T and CD4+ T-cell responses play a major role in antiviral immunity. It is therefore important to design vaccines that can induce T-cell's immune response (<a class=\"ref-link\" id=\"cSesardic_1993_a\" href=\"#rSesardic_1993_a\">Sesardic, 1993</a>). A total of",
            "T-cell epitopes were predicted on the spike protein (378 epitopes), the membrane protein (90 epitopes) and the envelop protein (31 epitopes); 48 of the 378 epitopes for the spike protein were located in the RBD region (Figure 1; Table 2; Table S2). There is no preference in certain genes or regions for T-cell epitope generation; no biased distribution of T-cell epitopes among HLA types were observed either. Among all T-cell epitopes, the epitope 869-MIAQYTSAL-877 in the spike protein was predicted to be able to bind to 17 HLA alleles. Most of the HLA alleles included in the present study were covered by these vaccine candidates, which suggested a wide population coverage.",
            "In terms of the distribution of the predicted epitopes against different HLA haplotypes, no significant differences were observed among different HLA haplotypes (Table S3). There were",
            "287, 208 and 195 epitopes predicted to be able to bind to HLA-A, HLA-B and HLA-C haplotypes, respectively. For the most popular five HLA types (HLA-A*11:01, HLA-A*24:02, HLA-C*07:02, HLA-A*02:01 and HLA-B*46:01), the counts for epitopes with binding affinity were 51, 49, 115, and 58."
        ],
        "3.3. Multi-epitope vaccine design": [
            "Based on the 19 B-cell epitopes and their 121 adjacent T-cell epitopes, 17 candidate vaccine peptides that contained both B-cell and T-cell epitopes were generated by our in-house software iNeo-Design. Most of the 17 candidate vaccine peptides contained one B-cell epitopes, except for",
            "FKNLREFVFKNIDGYFKIYSKHTPINLV had the largest count of T-cell epitopes, whereas the vaccine peptide SYGFQPTNGVGYQPYRVVVLSFELLHAPAT showed the highest HLA score, indicating their wide population coverage and promising efficacy.",
            "T-cell epitopes.",
            "In addition to the vaccine candidates involved both B-cell and T-cell epitopes, we also analysed the entire 499 core T-cell epitopes to generate another 102 vaccine peptides containing",
            "T-cell epitopes only. Based on both the epitope counts and HLA score, we eventually selected 13",
            "T-cell epitopes-only vaccine peptides.",
            "Taken together, a total of 30 peptide vaccine candidates were designed (Table 3). 26 of them were from the spike protein, two from the membrane protein and two from the envelop protein.",
            "Five peptides were located in the RBD region, indicating they were likely to induce the production of neutralizing antibody. The 30 vaccine peptides covered all structural proteins that may induce immune response against SARS-CoV-2 in theory; and the multi-peptide strategy we applied would better fit the genetic variability of the human immune system and reduce the risk of pathogen\u2019s escape through mutation (<a class=\"ref-link\" id=\"cSkwarczynski_2016_a\" href=\"#rSkwarczynski_2016_a\">Skwarczynski and Toth, 2016</a>)."
        ],
        "3.4. Interaction of predicted peptides with HLA alleles": [
            "To further inspect the binding stability of T-cell epitopes against HLA alleles, the T-cell epitopes involved in the above designed vaccine peptides were selected to conduct an interaction analysis.",
            "Figure 3 illustrated the docking results against the most popular HLA types for the two epitopes.",
            "from vaccines peptide 25 and 27 (Table 3; Table 4), which showed relatively higher HLA score.",
            "The MDockPep scores were between -148 ~ -136, indicating that the predicted crystal structures were stable. All epitopes were docked inside the catalytic pocket of the receptor protein. In particular, the epitope 1220-FIAGLIAIV-1228 from the spike protein possessed 2-5 stable hydrogen bonds with the HLA alleles; the epitope 4-FVSEETGTL-12 from the envelop protein possessed 4~5 stable hydrogen bonds (Table 4). Taken together, the epitopes included in our vaccine peptides can interact with the given HLA alleles by in silico prediction."
        ],
        "4. Conclusions": [
            "Vaccine design using an in silico prediction method is highly appreciated as it selects specific epitopes in proteins than conventional methods. In the present study, this reverse vaccinology approach was adopted to identify surface-exposed peptides, instead of targeting the whole pathogen which is obviously less efficient and effective. Immunogenic regions of antigenic epitopes of all proteins encoded by SARS-CoV-2 were screened to identify potential vaccine candidates. As a result, 17 vaccine peptides involving both T-cell epitopes and B-cell epitopes as well as 13 vaccine peptides involving T-cell epitopes only were successfully designed. These multi-epitope vaccines provided excellent candidates for the development of vaccines against",
            "SARS-CoV-2. Various formulation of vaccine can be rapidly manufactured, such as peptide, DNA and mRNA. However in vitro and in vivo trials are required to achieve the effectiveness of these vaccine peptides."
        ],
        "Acknowledgements": [
            "This work was supported by Zhejiang Provincial Natural Science Foundation of China.",
            "SC and FM conceived and designed the project. MQ, SZ, KL, RC, YS, KW, XZ and SZ analysed the data. YF and YL wrote the initial draft. All authors revised and approved the final manuscript."
        ],
        "References": [
            "Adam, K.-H., Kaaden, O., Strohmaier, K., 1978. Isolation of immunizing cyanogen bromide-peptides of foot-and-mouth disease virus. Biochemical and biophysical research communications 84, 677-683.",
            "Almofti, Y.A., Abd-elrahman, K.A., Gassmallah, S.A.E., Salih, M.A., 2018. Multi Epitopes",
            "Vaccine Prediction against Severe Acute Respiratory Syndrome (SARS) Coronavirus Using",
            "Immunoinformatics Approaches. American Journal of Microbiological Research 6, 94-114.",
            "Babcock, G.J., Esshaki, D.J., Thomas, W.D., Ambrosino, D.M., 2004. Amino acids 270 to 510 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction with receptor. J Virol 78, 4552-4560.",
            "Benvenuto, D., Giovannetti, M., Ciccozzi, A., Spoto, S., Angeletti, S., Ciccozzi, M., 2020. The",
            "2019\u2010new coronavirus epidemic: evidence for virus evolution. Journal of Medical Virology.",
            "Black, M., Trent, A., Tirrell, M., Olive, C., 2010. Advances in the design and delivery of peptide subunit vaccines with a focus on toll-like receptor agonists. Expert review of vaccines 9, 157-173.",
            "Buchholz, U.J., Bukreyev, A., Yang, L.J., Lamirande, E.W., Murphy, B.R., Subbarao, K., Collins, P.L., 2004. Contributions of the structural proteins of severe acute respiratory syndrome coronavirus to protective immunity. P Natl Acad Sci USA 101, 9804-9809.",
            "Chen, J., Liu, H., Yang, J., Chou, K.-C., 2007. Prediction of linear B-cell epitopes using amino acid pair antigenicity scale. Amino acids 33, 423-428.",
            "Chen, Y., Liu, Q., Guo, D., Emerging coronaviruses: genome structure, replication, and pathogenesis. Journal of Medical Virology.",
            "Dong, N., Yang, X., Ye, L., Chen, K., Chan, E.W.-C., Yang, M., Chen, S., 2020. Genomic and protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new coronavirus which caused a pneumonia outbreak in Wuhan, China. bioRxiv.",
            "Fieser, T.M., Tainer, J.A., Geysen, H.M., Houghten, R.A., Lerner, R.A., 1987. Influence of protein flexibility and peptide conformation on reactivity of monoclonal anti-peptide antibodies with a protein alpha-helix. Proceedings of the National Academy of Sciences 84, 8568-8572.",
            "<a class=\"ref-link\" id=\"cGorbalenya_2020_a\" href=\"#rGorbalenya_2020_a\">Gorbalenya, A.E., 2020</a>. <em>Severe acute respiratory syndrome-related coronavirus \u2013 The species and its viruses, a statement of the Coronavirus Study Group. bioRxiv, Gralinski, L.E., Menachery, V.D., 2020. Return of the Coronavirus: 2019-nCoV. Viruses 12, He, Y.X., Lu, H., Siddiqui, P., Zhou, Y.S., Jiang, S.B., 2005. Receptor-binding domain of severe acute respiratory syndrome coronavirus spike protein contains multiple conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol",
            "174, 4908-4915.",
            "Hoof, I., Peters, B., Sidney, J., Pedersen, L.E., Sette, A., Lund, O., Buus, S., Nielsen, M., 2009.",
            "NetMHCpan, a method for MHC class I binding prediction beyond humans. Immunogenetics",
            "61, 1.",
            "Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., 2020.",
            "Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The",
            "Lancet.",
            "Jespersen, M.C., Peters, B., Nielsen, M., Marcatili, P., 2017. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic acids research 45, W24-W29.",
            "Jiayuan Chen, J.S., Tungon Yau ,Chang Liu , Xin L, Qiang Zhao, Jishou Ruan , Gao Shan., 2020. Bioinformatics analysis of the Wuhan 2019 human coronavirus genome.",
            "Joseph T Wu*, K.L., Gabriel M Leung, 2020. Nowcasting and forecasting the potential domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a modelling study. The Lancet.",
            "Lamiable, A., Thevenet, P., Rey, J., Vavrusa, M., Derreumaux, P., Tuffery, P., 2016.",
            "PEP-FOLD3: faster de novo structure prediction for linear peptides in solution and in complex.",
            "Nucleic Acids Res 44, W449-454.",
            "Lerner, R.A., Green, N., Alexander, H., Liu, F.-T., Sutcliffe, J.G., Shinnick, T.M., 1981.",
            "Chemically synthesized peptides predicted from the nucleotide sequence of the hepatitis B virus genome elicit antibodies reactive with the native envelope protein of Dane particles.",
            "Proceedings of the National Academy of Sciences 78, 3403-3407.",
            "Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., Chen, J., Meng, Y., Wang, J., Lin, Y., Yuan, J., Xie, Z., Ma, J., Liu, W.J., Wang, D., Xu, W., Holmes, E.C., Gao, G.F., Wu, G., Chen, W., Shi, W., Tan, W., 2020. Genomic characterisation and epidemiology of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet.",
            "Organization, W.H., 2020. Surveillance case definitions for human infection with novel coronavirus (nCoV): interim guidance v1, January 2020. , in: Organization, W.H. (Ed.). World",
            "Health Organization, Geneva.",
            "<a class=\"ref-link\" id=\"cPerlman_2020_a\" href=\"#rPerlman_2020_a\">Perlman, S., 2020</a>. Another Decade, Another Coronavirus. New England Journal of Medicine.",
            "Purcell, A.W., McCluskey, J., Rossjohn, J., 2007. More than one reason to rethink the use of peptides in vaccine design. Nat Rev Drug Discov 6, 404-414.",
            "<a class=\"ref-link\" id=\"cSaif_1993_a\" href=\"#rSaif_1993_a\">Saif, L.J., 1993</a>. Coronavirus Immunogens. Vet Microbiol 37, 285-297.",
            "<a class=\"ref-link\" id=\"cSesardic_1993_a\" href=\"#rSesardic_1993_a\">Sesardic, D., 1993</a>. Synthetic peptide vaccines. Journal of medical microbiology 39, 241-242.",
            "<a class=\"ref-link\" id=\"cSkwarczynski_2016_a\" href=\"#rSkwarczynski_2016_a\">Skwarczynski, M., Toth, I., 2016</a>. Peptide-based synthetic vaccines. Chemical science 7, 842-854.",
            "Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., 2020.",
            "Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human monoclonal antibody. bioRxiv.",
            "Vita, R., Overton, J.A., Greenbaum, J.A., Ponomarenko, J., Clark, J.D., Cantrell, J.R., Wheeler, D.K., Gabbard, J.L., Hix, D., Sette, A., 2015. The immune epitope database (IEDB) 3.0.",
            "Nucleic acids research 43, D405-D412.",
            "Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F.T., de Beer, T.A.P., Rempfer, C., Bordoli, L., Lepore, R., Schwede, T., 2018. SWISS-MODEL: homology modelling of protein structures and complexes. Nucleic Acids Res 46, W296-W303.",
            "Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.-L., Abiona, O., Graham, B.S., McLellan, J.S., 2020. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion",
            "Conformation. bioRxiv, 2020.2002.2011.944462.",
            "Xu, X., Yan, C., Zou, X., 2018. MDockPeP: An ab-initio protein-peptide docking server. Journal of computational chemistry 39, 2409-2413.",
            "Zhao, Y., Zhao, Z., Wang, Y., Zhou, Y., Ma, Y., Zuo, W., 2020. Single-cell RNA expression profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv.",
            "Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., Huang, C.-L., 2020. Discovery of a novel coronavirus associated with the recent pneumonia outbreak in humans and its potential bat origin. bioRxiv.",
            "Figure legends",
            "Fig. 1. Distribution of B-cell and T-cell epitopes. The outermost circle (light blue) stands for the",
            "T-cell epitope count. The 2rd outer circle stands for Emini (in red) and Kolaskar (in green) score used to evaluate the B-cell epitopes. The 3rd circle marked the name of the viral proteins. The",
            "4th-6th circles stands for HLA-A (in blue), HLA-B (in green), and HLA-C (in yellow) scores; the points closer to the center indicates a lower score.",
            "Fig. 2. Locations of the recognized B cell epitopes on the viral spike protein (a), envelop protein (b) and membrane protein (c). The transparent cartoon models display the predicted 3D structure; the colorful balls marks the position of the recognized epitopes.",
            "Fig. 3. Interaction between the predicted peptides (by yellow sticks) and different HLA alleles (by green cartoons). Amino acids were labeled adjacent to the contact sites. Table 3 displays the detailed docking information.",
            "Epitope",
            "Protein",
            "Start",
            "End",
            "Peptipe",
            "Emini",
            "Kolaskar",
            "B1",
            "Spike",
            "TTRTQLPPAYTNSFTRGVYYPDKVF",
            "1.028",
            "B2",
            "VYFASTEKSN",
            "1.019",
            "B3",
            "KHTP",
            "1.002",
            "B4",
            "DEVRQIAPGQTGKIADYNYKLPDDFT",
            "1.001",
            "B5",
            "SYGFQPTNGVGYQP",
            "1.02",
            "B6",
            "CASYQTQTNSPRRARSVA",
            "1.027",
            "B7",
            "AVEQDKNTQEVF",
            "1.011",
            "B8",
            "QIYKTPPIKDFGG",
            "1.006",
            "B9",
            "ILPDPSKPSKRS",
            "B10",
            "FPQSAPH",
            "1.059",
            "B11",
            "VPAQEKNFTTAPAICHDGKAHFPR",
            "1.03",
            "B12",
            "NFYEPQIITTDNTFVS",
            "1.007",
            "Table 1. B-cell epitope candidates",
            "NTVYDPLQPELDSFKEE",
            "B14",
            "DKYFKNHTSPDVDLGDISGI",
            "B15",
            "AKNL",
            "1.005",
            "B16",
            "LGKYEQY",
            "1.035",
            "B17",
            "KFDEDDSEPVL",
            "1.003",
            "B18",
            "KNLNSSRV",
            "B19",
            "SRTL",
            "Note: Epitopes B4 and B5 are located within the RBD region.",
            "B13",
            "Count of T-cell",
            "No of epitope per",
            "HLA Types",
            "Epitope overage",
            "Epitope residue",
            "93.01%",
            "Membrane",
            "96.00%",
            "Envelop",
            "94.14%",
            "Count",
            "Table 2. Distribution of T-cell epitopes among three structural proteins",
            "Peptide",
            "Vaccine peptide",
            "P1",
            "P2",
            "P3",
            "P4",
            "Count of",
            "T",
            "B",
            "HLA",
            "Epitopes",
            "Score",
            "TTRTQLPPAYTNSFTRGVYYPDKVFRSS",
            "GTKRFDNPVLPFNDGVYFASTEKSNK",
            "LIVNNATNVVIKVCEFQFCNDPFLGVKK",
            "GVYYHKNNKSWMESEFRVYSSANNCTFEY",
            "P5",
            "FKNLREFVFKNIDGYFKIYSKHTP",
            "P6",
            "WTAGAAAYYVGYLQPRTFLLKYKKKKK",
            "P7",
            "KGIYQTSNFRVQPTESIVRFPNITNLCP",
            "P8 *",
            "RISNCVADYSVLYNSASFSTFKCYGVSPTK",
            "P9 *",
            "DEVRQIAPGQTGKIADYNYKLPDDFTGKKK",
            "P10 *",
            "NYNYLYRLFRKSNLKPFERDISTEI",
            "P11 *",
            "TPCNGVEGFNCYFPLQSYGFQPTNGVGYKK",
            "P12 *",
            "SYGFQPTNGVGYQPYRVVVLSFELLHAPAT",
            "Table 3. Candidate vaccine peptides",
            "HADQLTPTWRVYSTGSNVFQTRAGCLIG",
            "P14",
            "CASYQTQTNSPRRARSVASQSIIAYTMSL",
            "P15",
            "AVEQDKNTQEVFAQVKQIYKTPPIKDFGGK",
            "P16",
            "ILPDPSKPSKRSFIEDLLFNKVTLADAGFK",
            "P17",
            "IPFAMQMAYRFNGIGVTQNVLYENQKLI",
            "P18",
            "QLSSNFGAISSVLNDILSRLDKVEAEVKKK",
            "P19",
            "FPQSAPHGVVFLHVTYVPAQEK",
            "P20",
            "VPAQEKNFTTAPAICHDGKAHFPREGVFV",
            "P21",
            "FVSNGTHWFVTQRNFYEPQIITTDNTFVSK",
            "P22",
            "NTVYDPLQPELDSFKEELDKYKKKKK",
            "P23",
            "DKYFKNHTSPDVDLGDISGINASVVNIQKK",
            "P24",
            "AKNLNESLIDLQELGKYEQYIKWPWYIWKK",
            "P25",
            "IWLGFIAGLIAIVMVTIMLCKKKKKKKKKK",
            "P26",
            "KKKKCCSCLKGCCSCGSCCKFDEDDSEPVL",
            "P13",
            "FVSEETGTLIVNSVLLFLAFVVFLKKKKKK",
            "P28",
            "NIVNVSLVKPSFYVYSRVKNLNSSRV",
            "P29",
            "VPLHGTILTRPLLESELVIGAVILRGHLRK",
            "P30",
            "SRTLSYYKLGASQRVAGDSGFAAYSRYRI",
            "Note: Peptide labeled by asterisks (*) are located within the RBD region.",
            "P27",
            "HLA type",
            "HLA Score",
            "ITScorePeP",
            "Contact residues a",
            "FIAGLIAIV",
            "HLA-A*02:01",
            "-144.2",
            "PHE-1,GLY-4,LEU-5,ILE-6,ALA-7 b",
            "HLA-B*46:01",
            "-138.2",
            "ILE-6,VAL-9 c",
            "HLA-C*03:04",
            "-146.6",
            "PHE-1,ALA-3,ILE-8,VAL-9 d",
            "FVSEETGTL",
            "HLA-A*02:06",
            "-147.7",
            "PHE-1,VAL-2,SER-3,GLU-4,THR-6 e",
            "-140.2",
            "PHE-1,SER-3,GLU-4,THR-6,THR-8 f",
            "HLA-C*07:02",
            "-136.7",
            "PHE-1,GLU-4,THR-8,LEU-9",
            "Panel in",
            "Fig. 3",
            "Table 4. Docking results for T-cell epitope P25 and P27 against three HLA types"
        ]
    },
    "participants": [
        {
            "participant": "infection cases",
            "number": 74000,
            "context": ". <mark class=\"stats\">A new coronavirus SARS-CoV-2, recently discovered in Wuhan, China, has caused over 74000 infection cases and 2000 deaths</mark>. Due to the rapidly growing cases and the unavailability of specific therapy, there is a desperate need for vaccines to combat the epidemic of SARS-CoV-2"
        }
    ],
    "statistics": [
        {
            "tests": {
                "context": "<mark class=\"stats\">The antigenic sites were determined with Kolaskar method (Chen et al, 2007)</mark>",
                "tests": [
                    {
                        "test": "Kolaskar method"
                    }
                ]
            }
        }
    ],
    "keywords": [
        "hla allele",
        "vaccine peptide",
        "severe acute respiratory syndrome",
        "coronavirus",
        "antigenic",
        "novel coronavirus-infected pneumonia",
        "vaccine design",
        "SARS-CoV-2",
        "vaccine",
        "SARS",
        "immunoinformatics",
        "coronavirus disease 2019",
        "epitope",
        "novel coronavirus",
        "Acute Respiratory syndrome",
        "t cell epitope",
        "sars cov",
        "b cell epitope",
        "receptor binding domain",
        "pneumonia",
        "angiotensin-converting enzyme 2"
    ],
    "keyword_relevance": {
        "epitope": 0.34657039711191334,
        "vaccine": 0.19494584837545126,
        "SARS": 0.08664259927797834,
        "coronavirus": 0.07220216606498195,
        "SARS-CoV-2": 0.06498194945848375,
        "vaccine peptide": 0.061371841155234655,
        "receptor binding domain": 0.039711191335740074,
        "antigenic": 0.02888086642599278,
        "novel coronavirus": 0.02527075812274368,
        "vaccine design": 0.018050541516245487,
        "angiotensin-converting enzyme 2": 0.01444043321299639,
        "severe acute respiratory syndrome": 0.010830324909747292,
        "coronavirus disease 2019": 0.010830324909747292,
        "pneumonia": 0.010830324909747292,
        "novel coronavirus-infected pneumonia": 0.007220216606498195,
        "immunoinformatics": 0.007220216606498195,
        "hla allele": 0.0,
        "Acute Respiratory syndrome": 0.0,
        "t cell epitope": 0.0,
        "sars cov": 0.0,
        "b cell epitope": 0.0
    },
    "species": [],
    "summary": [
        "<h2 style=\"display: inline\">Introduction:</h2> Since December 2019, Wuhan City, Hubei Province, China has become the center of an outbreak of viral lung infections caused by a new type of coronavirus, SARS-CoV-2 (<a class=\"ref-link\" id=\"cGorbalenya_2020_a\" href=\"#rGorbalenya_2020_a\">Gorbalenya, 2020</a>; Joseph T Wu*, 2020; Organization, 2020; <a class=\"ref-link\" id=\"cPerlman_2020_a\" href=\"#rPerlman_2020_a\">Perlman, 2020</a>).The outbreak has so far infected over 74000 patients, and has spread to approximately 30 countries/regions worldwide.",
        "Due to lack of anti-viral drugs or vaccines, control measures have been relying on the rapid detection and isolation of symptomatic cases (Chen et al.).",
        "In this context, a safe and efficacious vaccine is urgently required.",
        "Computation-based method enable them to start from analysis of viral genome, without the need to grow pathogens and speeding up the entire process",
        "<h2 style=\"display: inline\">Methods:</h2> The genome sequence of SARS-CoV-2 isolate Wuhan-Hu-1 was retrieved from the NCBI database under the accession number MN908947.",
        "Gene and protein sequences were acquired according to the annotation.",
        "The RBD region for the spike protein was referred to as the fragment from 347 to 520 amino acid (Lu et al, 2020).",
        "The online tool in IEDB (Immune-Epitope-Database And Analysis-Resource) was used for the analysis of the conserved regions of the candidate epitopes (Vita et al, 2015).",
        "Prediction of linear",
        "<h2 style=\"display: inline\">Conclusion:</h2> Vaccine design using an in silico prediction method is highly appreciated as it selects specific epitopes in proteins than conventional methods.",
        "Immunogenic regions of antigenic epitopes of all proteins encoded by SARS-CoV-2 were screened to identify potential vaccine candidates.",
        "17 vaccine peptides involving both T-cell epitopes and B-cell epitopes as well as 13 vaccine peptides involving T-cell epitopes only were successfully designed.",
        "These multi-epitope vaccines provided excellent candidates for the development of vaccines against.",
        "In vitro and in vivo trials are required to achieve the effectiveness of these vaccine peptides"
    ],
    "structured_summary": {
        "Introduction": [
            "Since December 2019, Wuhan City, Hubei Province, China has become the center of an outbreak of viral lung infections caused by a new type of coronavirus, SARS-CoV-2 (<a class=\"ref-link\" id=\"cGorbalenya_2020_a\" href=\"#rGorbalenya_2020_a\">Gorbalenya, 2020</a>; Joseph T Wu*, 2020; Organization, 2020; <a class=\"ref-link\" id=\"cPerlman_2020_a\" href=\"#rPerlman_2020_a\">Perlman, 2020</a>).The outbreak has so far infected over 74000 patients, and has spread to approximately 30 countries/regions worldwide.",
            "Due to lack of anti-viral drugs or vaccines, control measures have been relying on the rapid detection and isolation of symptomatic cases (Chen et al.).",
            "In this context, a safe and efficacious vaccine is urgently required.",
            "Computation-based method enable them to start from analysis of viral genome, without the need to grow pathogens and speeding up the entire process"
        ],
        "Methods": [
            "The genome sequence of SARS-CoV-2 isolate Wuhan-Hu-1 was retrieved from the NCBI database under the accession number MN908947.",
            "Gene and protein sequences were acquired according to the annotation.",
            "The RBD region for the spike protein was referred to as the fragment from 347 to 520 amino acid (Lu et al, 2020).",
            "The online tool in IEDB (Immune-Epitope-Database And Analysis-Resource) was used for the analysis of the conserved regions of the candidate epitopes (Vita et al, 2015).",
            "Prediction of linear"
        ],
        "Conclusion": [
            "Vaccine design using an in silico prediction method is highly appreciated as it selects specific epitopes in proteins than conventional methods.",
            "Immunogenic regions of antigenic epitopes of all proteins encoded by SARS-CoV-2 were screened to identify potential vaccine candidates.",
            "17 vaccine peptides involving both T-cell epitopes and B-cell epitopes as well as 13 vaccine peptides involving T-cell epitopes only were successfully designed.",
            "These multi-epitope vaccines provided excellent candidates for the development of vaccines against.",
            "In vitro and in vivo trials are required to achieve the effectiveness of these vaccine peptides"
        ]
    },
    "reference_links": [
        {
            "id": "221",
            "alt_id": "Almofti_et+al_2018_a",
            "entry": "221 Almofti, Y.A., Abd-elrahman, K.A., Gassmallah, S.A.E., Salih, M.A., 2018. Multi Epitopes 222 Vaccine Prediction against Severe Acute Respiratory Syndrome (SARS) Coronavirus Using 223 Immunoinformatics Approaches. American Journal of Microbiological Research 6, 94-114.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Almofti%2C%20Y.A.%20Abd-elrahman%2C%20K.A.%20Gassmallah%2C%20S.A.E.%20Salih%2C%20M.A.%20Multi%20Epitopes%20222%20Vaccine%20Prediction%20against%20Severe%20Acute%20Respiratory%20Syndrome%20%28SARS%29%20Coronavirus%20Using%20223%20Immunoinformatics%20Approaches%202018",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Almofti%2C%20Y.A.%20Abd-elrahman%2C%20K.A.%20Gassmallah%2C%20S.A.E.%20Salih%2C%20M.A.%20Multi%20Epitopes%20222%20Vaccine%20Prediction%20against%20Severe%20Acute%20Respiratory%20Syndrome%20%28SARS%29%20Coronavirus%20Using%20223%20Immunoinformatics%20Approaches%202018",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Almofti%2C%20Y.A.%20Abd-elrahman%2C%20K.A.%20Gassmallah%2C%20S.A.E.%20Salih%2C%20M.A.%20Multi%20Epitopes%20222%20Vaccine%20Prediction%20against%20Severe%20Acute%20Respiratory%20Syndrome%20%28SARS%29%20Coronavirus%20Using%20223%20Immunoinformatics%20Approaches%202018"
        },
        {
            "id": "Babcock_et+al_2004_a",
            "alt_id": "2",
            "entry": "Babcock, G.J., Esshaki, D.J., Thomas, W.D., Ambrosino, D.M., 2004. Amino acids 270 to 510 225 of the severe acute respiratory syndrome coronavirus spike protein are required for interaction 226 with receptor. J Virol 78, 4552-4560.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Babcock%2C%20G.J.%20Esshaki%2C%20D.J.%20Thomas%2C%20W.D.%20Ambrosino%2C%20D.M.%20Amino%20acids%20270%20to%20510%20225%20of%20the%20severe%20acute%20respiratory%20syndrome%20coronavirus%20spike%20protein%20are%20required%20for%20interaction%20226%20with%20receptor%202004",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Babcock%2C%20G.J.%20Esshaki%2C%20D.J.%20Thomas%2C%20W.D.%20Ambrosino%2C%20D.M.%20Amino%20acids%20270%20to%20510%20225%20of%20the%20severe%20acute%20respiratory%20syndrome%20coronavirus%20spike%20protein%20are%20required%20for%20interaction%20226%20with%20receptor%202004",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Babcock%2C%20G.J.%20Esshaki%2C%20D.J.%20Thomas%2C%20W.D.%20Ambrosino%2C%20D.M.%20Amino%20acids%20270%20to%20510%20225%20of%20the%20severe%20acute%20respiratory%20syndrome%20coronavirus%20spike%20protein%20are%20required%20for%20interaction%20226%20with%20receptor%202004"
        },
        {
            "id": "Benvenuto_2019_a",
            "alt_id": "3",
            "entry": "Benvenuto, D., Giovannetti, M., Ciccozzi, A., Spoto, S., Angeletti, S., Ciccozzi, M., 2020. The 228 2019\u2010new coronavirus epidemic: evidence for virus evolution. Journal of Medical Virology.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Benvenuto%20D%20Giovannetti%20M%20Ciccozzi%20A%20Spoto%20S%20Angeletti%20S%20Ciccozzi%20M%202020%20The%20228%202019new%20coronavirus%20epidemic%20evidence%20for%20virus%20evolution%20Journal%20of%20Medical%20Virology",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Benvenuto%20D%20Giovannetti%20M%20Ciccozzi%20A%20Spoto%20S%20Angeletti%20S%20Ciccozzi%20M%202020%20The%20228%202019new%20coronavirus%20epidemic%20evidence%20for%20virus%20evolution%20Journal%20of%20Medical%20Virology",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Benvenuto%20D%20Giovannetti%20M%20Ciccozzi%20A%20Spoto%20S%20Angeletti%20S%20Ciccozzi%20M%202020%20The%20228%202019new%20coronavirus%20epidemic%20evidence%20for%20virus%20evolution%20Journal%20of%20Medical%20Virology"
        },
        {
            "id": "Black_et+al_2010_a",
            "alt_id": "4",
            "entry": "Black, M., Trent, A., Tirrell, M., Olive, C., 2010. Advances in the design and delivery of peptide 230 subunit vaccines with a focus on toll-like receptor agonists. Expert review of vaccines 9, 231 157-173.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Black%2C%20M.%20Trent%2C%20A.%20Tirrell%2C%20M.%20Olive%2C%20C.%20Advances%20in%20the%20design%20and%20delivery%20of%20peptide%20230%20subunit%20vaccines%20with%20a%20focus%20on%20toll-like%20receptor%20agonists%202010",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Black%2C%20M.%20Trent%2C%20A.%20Tirrell%2C%20M.%20Olive%2C%20C.%20Advances%20in%20the%20design%20and%20delivery%20of%20peptide%20230%20subunit%20vaccines%20with%20a%20focus%20on%20toll-like%20receptor%20agonists%202010",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Black%2C%20M.%20Trent%2C%20A.%20Tirrell%2C%20M.%20Olive%2C%20C.%20Advances%20in%20the%20design%20and%20delivery%20of%20peptide%20230%20subunit%20vaccines%20with%20a%20focus%20on%20toll-like%20receptor%20agonists%202010"
        },
        {
            "id": "Buchholz_2004_a",
            "alt_id": "5",
            "entry": "Buchholz, U.J., Bukreyev, A., Yang, L.J., Lamirande, E.W., Murphy, B.R., Subbarao, K., 233 Collins, P.L., 2004. Contributions of the structural proteins of severe acute respiratory 234 syndrome coronavirus to protective immunity. P Natl Acad Sci USA 101, 9804-9809.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Buchholz%20UJ%20Bukreyev%20A%20Yang%20LJ%20Lamirande%20EW%20Murphy%20BR%20Subbarao%20K%20233%20Collins%20PL%202004%20Contributions%20of%20the%20structural%20proteins%20of%20severe%20acute%20respiratory%20234%20syndrome%20coronavirus%20to%20protective%20immunity%20P%20Natl%20Acad%20Sci%20USA%20101%2098049809",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Buchholz%20UJ%20Bukreyev%20A%20Yang%20LJ%20Lamirande%20EW%20Murphy%20BR%20Subbarao%20K%20233%20Collins%20PL%202004%20Contributions%20of%20the%20structural%20proteins%20of%20severe%20acute%20respiratory%20234%20syndrome%20coronavirus%20to%20protective%20immunity%20P%20Natl%20Acad%20Sci%20USA%20101%2098049809",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Buchholz%20UJ%20Bukreyev%20A%20Yang%20LJ%20Lamirande%20EW%20Murphy%20BR%20Subbarao%20K%20233%20Collins%20PL%202004%20Contributions%20of%20the%20structural%20proteins%20of%20severe%20acute%20respiratory%20234%20syndrome%20coronavirus%20to%20protective%20immunity%20P%20Natl%20Acad%20Sci%20USA%20101%2098049809"
        },
        {
            "id": "Chen_et+al_2007_a",
            "alt_id": "6",
            "entry": "Chen, J., Liu, H., Yang, J., Chou, K.-C., 2007. Prediction of linear B-cell epitopes using amino 236 acid pair antigenicity scale. Amino acids 33, 423-428.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Chen%2C%20J.%20Liu%2C%20H.%20Yang%2C%20J.%20Chou%2C%20K.-C.%20Prediction%20of%20linear%20B-cell%20epitopes%20using%20amino%20236%20acid%20pair%20antigenicity%20scale%202007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Chen%2C%20J.%20Liu%2C%20H.%20Yang%2C%20J.%20Chou%2C%20K.-C.%20Prediction%20of%20linear%20B-cell%20epitopes%20using%20amino%20236%20acid%20pair%20antigenicity%20scale%202007",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Chen%2C%20J.%20Liu%2C%20H.%20Yang%2C%20J.%20Chou%2C%20K.-C.%20Prediction%20of%20linear%20B-cell%20epitopes%20using%20amino%20236%20acid%20pair%20antigenicity%20scale%202007"
        },
        {
            "id": "Chen_et+al_0000_a",
            "alt_id": "7",
            "entry": "Chen, Y., Liu, Q., Guo, D., Emerging coronaviruses: genome structure, replication, and 238 pathogenesis. Journal of Medical Virology.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Chen%2C%20Y.%20Liu%2C%20Q.%20Guo%2C%20D.%20Emerging%20coronaviruses%3A%20genome%20structure%2C%20replication%2C%20and%20238%20pathogenesis",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Chen%2C%20Y.%20Liu%2C%20Q.%20Guo%2C%20D.%20Emerging%20coronaviruses%3A%20genome%20structure%2C%20replication%2C%20and%20238%20pathogenesis",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Chen%2C%20Y.%20Liu%2C%20Q.%20Guo%2C%20D.%20Emerging%20coronaviruses%3A%20genome%20structure%2C%20replication%2C%20and%20238%20pathogenesis"
        },
        {
            "id": "Dong_2019_a",
            "alt_id": "8",
            "entry": "Dong, N., Yang, X., Ye, L., Chen, K., Chan, E.W.-C., Yang, M., Chen, S., 2020. Genomic and 240 protein structure modelling analysis depicts the origin and infectivity of 2019-nCoV, a new 241 coronavirus which caused a pneumonia outbreak in Wuhan, China. bioRxiv.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Dong%20N%20Yang%20X%20Ye%20L%20Chen%20K%20Chan%20EWC%20Yang%20M%20Chen%20S%202020%20Genomic%20and%20240%20protein%20structure%20modelling%20analysis%20depicts%20the%20origin%20and%20infectivity%20of%202019nCoV%20a%20new%20241%20coronavirus%20which%20caused%20a%20pneumonia%20outbreak%20in%20Wuhan%20China%20bioRxiv"
        },
        {
            "id": "Fieser_et+al_1987_a",
            "alt_id": "9",
            "entry": "Fieser, T.M., Tainer, J.A., Geysen, H.M., Houghten, R.A., Lerner, R.A., 1987. Influence of 243 protein flexibility and peptide conformation on reactivity of monoclonal anti-peptide antibodies with a protein alpha-helix. Proceedings of the National Academy of Sciences 84, 8568-8572.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Fieser%2C%20T.M.%20Tainer%2C%20J.A.%20Geysen%2C%20H.M.%20Houghten%2C%20R.A.%20Influence%20of%20243%20protein%20flexibility%20and%20peptide%20conformation%20on%20reactivity%20of%20monoclonal%20anti-peptide%20antibodies%20with%20a%20protein%20alpha-helix%201987",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Fieser%2C%20T.M.%20Tainer%2C%20J.A.%20Geysen%2C%20H.M.%20Houghten%2C%20R.A.%20Influence%20of%20243%20protein%20flexibility%20and%20peptide%20conformation%20on%20reactivity%20of%20monoclonal%20anti-peptide%20antibodies%20with%20a%20protein%20alpha-helix%201987",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Fieser%2C%20T.M.%20Tainer%2C%20J.A.%20Geysen%2C%20H.M.%20Houghten%2C%20R.A.%20Influence%20of%20243%20protein%20flexibility%20and%20peptide%20conformation%20on%20reactivity%20of%20monoclonal%20anti-peptide%20antibodies%20with%20a%20protein%20alpha-helix%201987"
        },
        {
            "id": "Gorbalenya_2020_a",
            "alt_id": "10",
            "entry": "Gorbalenya, A.E., 2020. <em>Severe acute respiratory syndrome-related coronavirus \u2013 The 246 species and its viruses, a statement of the Coronavirus Study Group. bioRxiv, 247 2020.2002.2007.937862.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Gorbalenya%20AE%202020%20emSevere%20acute%20respiratory%20syndromerelated%20coronavirus%20%20The%20246%20species%20and%20its%20viruses%20a%20statement%20of%20the%20Coronavirus%20Study%20Group%20bioRxiv%20247%20202020022007937862",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Gorbalenya%20AE%202020%20emSevere%20acute%20respiratory%20syndromerelated%20coronavirus%20%20The%20246%20species%20and%20its%20viruses%20a%20statement%20of%20the%20Coronavirus%20Study%20Group%20bioRxiv%20247%20202020022007937862",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Gorbalenya%20AE%202020%20emSevere%20acute%20respiratory%20syndromerelated%20coronavirus%20%20The%20246%20species%20and%20its%20viruses%20a%20statement%20of%20the%20Coronavirus%20Study%20Group%20bioRxiv%20247%20202020022007937862"
        },
        {
            "id": "248",
            "alt_id": "Gralinski_2019_a",
            "entry": "248 Gralinski, L.E., Menachery, V.D., 2020. Return of the Coronavirus: 2019-nCoV. Viruses 12, 249 135.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Gralinski%20LE%20Menachery%20VD%202020%20Return%20of%20the%20Coronavirus%202019nCoV%20Viruses%2012%20249%20135",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Gralinski%20LE%20Menachery%20VD%202020%20Return%20of%20the%20Coronavirus%202019nCoV%20Viruses%2012%20249%20135",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Gralinski%20LE%20Menachery%20VD%202020%20Return%20of%20the%20Coronavirus%202019nCoV%20Viruses%2012%20249%20135"
        },
        {
            "id": "He_et+al_2005_a",
            "alt_id": "12",
            "entry": "He, Y.X., Lu, H., Siddiqui, P., Zhou, Y.S., Jiang, S.B., 2005. Receptor-binding domain of 251 severe acute respiratory syndrome coronavirus spike protein contains multiple 252 conformation-dependent epitopes that induce highly potent neutralizing antibodies. J Immunol 253 174, 4908-4915.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=He%2C%20Y.X.%20Lu%2C%20H.%20Siddiqui%2C%20P.%20Zhou%2C%20Y.S.%20Receptor-binding%20domain%20of%20251%20severe%20acute%20respiratory%20syndrome%20coronavirus%20spike%20protein%20contains%20multiple%20252%20conformation-dependent%20epitopes%20that%20induce%20highly%20potent%20neutralizing%20antibodies%202005",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=He%2C%20Y.X.%20Lu%2C%20H.%20Siddiqui%2C%20P.%20Zhou%2C%20Y.S.%20Receptor-binding%20domain%20of%20251%20severe%20acute%20respiratory%20syndrome%20coronavirus%20spike%20protein%20contains%20multiple%20252%20conformation-dependent%20epitopes%20that%20induce%20highly%20potent%20neutralizing%20antibodies%202005",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=He%2C%20Y.X.%20Lu%2C%20H.%20Siddiqui%2C%20P.%20Zhou%2C%20Y.S.%20Receptor-binding%20domain%20of%20251%20severe%20acute%20respiratory%20syndrome%20coronavirus%20spike%20protein%20contains%20multiple%20252%20conformation-dependent%20epitopes%20that%20induce%20highly%20potent%20neutralizing%20antibodies%202005"
        },
        {
            "id": "Hoof_et+al_2009_a",
            "alt_id": "13",
            "entry": "Hoof, I., Peters, B., Sidney, J., Pedersen, L.E., Sette, A., Lund, O., Buus, S., Nielsen, M., 2009.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Hoof%20I%20Peters%20B%20Sidney%20J%20Pedersen%20LE%20Sette%20A%20Lund%20O%20Buus%20S%20Nielsen%20M%202009"
        },
        {
            "id": "Huang_et+al_2020_a",
            "alt_id": "14",
            "entry": "Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., 2020.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Huang%20C%20Wang%20Y%20Li%20X%20Ren%20L%20Zhao%20J%20Hu%20Y%20Zhang%20L%20Fan%20G%20Xu%20J%20Gu%20X%202020"
        },
        {
            "id": "258",
            "alt_id": "258_2019_a",
            "entry": "258 Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The 259 Lancet.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Clinical%20features%20of%20patients%20infected%20with%202019%20novel%20coronavirus%20in%20Wuhan%20China%20The%20259%20Lancet"
        },
        {
            "id": "Jespersen_et+al_2017_a",
            "alt_id": "16",
            "entry": "Jespersen, M.C., Peters, B., Nielsen, M., Marcatili, P., 2017. BepiPred-2.0: improving 261 sequence-based B-cell epitope prediction using conformational epitopes. Nucleic acids 262 research 45, W24-W29.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Jespersen%2C%20M.C.%20Peters%2C%20B.%20Nielsen%2C%20M.%20Marcatili%2C%20P.%20BepiPred-%202.0%3A%20improving%20261%20sequence-based%20B-cell%20epitope%20prediction%20using%20conformational%20epitopes%202017",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Jespersen%2C%20M.C.%20Peters%2C%20B.%20Nielsen%2C%20M.%20Marcatili%2C%20P.%20BepiPred-%202.0%3A%20improving%20261%20sequence-based%20B-cell%20epitope%20prediction%20using%20conformational%20epitopes%202017",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Jespersen%2C%20M.C.%20Peters%2C%20B.%20Nielsen%2C%20M.%20Marcatili%2C%20P.%20BepiPred-%202.0%3A%20improving%20261%20sequence-based%20B-cell%20epitope%20prediction%20using%20conformational%20epitopes%202017"
        },
        {
            "id": "Jiayuan_2019_a",
            "alt_id": "17",
            "entry": "Jiayuan Chen, J.S., Tungon Yau,Chang Liu, Xin L, Qiang Zhao, Jishou Ruan, Gao Shan., 2020. Bioinformatics analysis of the Wuhan 2019 human coronavirus genome.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Jiayuan%20Chen%20JS%20Tungon%20YauChang%20Liu%20Xin%20L%20Qiang%20Zhao%20Jishou%20Ruan%20Gao%20Shan%202020%20Bioinformatics%20analysis%20of%20the%20Wuhan%202019%20human%20coronavirus%20genome"
        },
        {
            "id": "Joseph_2019_a",
            "alt_id": "18",
            "entry": "Joseph T Wu*, K.L., Gabriel M Leung, 2020. Nowcasting and forecasting the potential 266 domestic and international spread of the 2019-nCoV outbreak originating in Wuhan, China: a 267 modelling study. The Lancet.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Joseph%20T%20Wu%20KL%20Gabriel%20M%20Leung%202020%20Nowcasting%20and%20forecasting%20the%20potential%20266%20domestic%20and%20international%20spread%20of%20the%202019nCoV%20outbreak%20originating%20in%20Wuhan%20China%20a%20267%20modelling%20study%20The%20Lancet"
        },
        {
            "id": "Lamiable_et+al_2016_a",
            "alt_id": "19",
            "entry": "Lamiable, A., Thevenet, P., Rey, J., Vavrusa, M., Derreumaux, P., Tuffery, P., 2016.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Lamiable%20A%20Thevenet%20P%20Rey%20J%20Vavrusa%20M%20Derreumaux%20P%20Tuffery%20P%202016"
        },
        {
            "id": "Lerner_et+al_1981_a",
            "alt_id": "20",
            "entry": "Lerner, R.A., Green, N., Alexander, H., Liu, F.-T., Sutcliffe, J.G., Shinnick, T.M., 1981.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Lerner%20RA%20Green%20N%20Alexander%20H%20Liu%20FT%20Sutcliffe%20JG%20Shinnick%20TM%201981",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Lerner%20RA%20Green%20N%20Alexander%20H%20Liu%20FT%20Sutcliffe%20JG%20Shinnick%20TM%201981",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Lerner%20RA%20Green%20N%20Alexander%20H%20Liu%20FT%20Sutcliffe%20JG%20Shinnick%20TM%201981"
        },
        {
            "id": "274",
            "alt_id": "274_0000_b",
            "entry": "274 Proceedings of the National Academy of Sciences 78, 3403-3407.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%2078%2034033407",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%2078%2034033407",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Proceedings%20of%20the%20National%20Academy%20of%20Sciences%2078%2034033407"
        },
        {
            "id": "Lu_2020_a",
            "alt_id": "22",
            "entry": "Lu, R., Zhao, X., Li, J., Niu, P., Yang, B., Wu, H., Wang, W., Song, H., Huang, B., Zhu, N., Bi, 276 Y., Ma, X., Zhan, F., Wang, L., Hu, T., Zhou, H., Hu, Z., Zhou, W., Zhao, L., Chen, J., Meng, Y., 277 Wang, J., Lin, Y., Yuan, J., Xie, Z., Ma, J., Liu, W.J., Wang, D., Xu, W., Holmes, E.C., Gao, 278 G.F., Wu, G., Chen, W., Shi, W., Tan, W., 2020. Genomic characterisation and epidemiology 279 of 2019 novel coronavirus: implications for virus origins and receptor binding. Lancet.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Lu%20R%20Zhao%20X%20Li%20J%20Niu%20P%20Yang%20B%20Wu%20H%20Wang%20W%20Song%20H%20Huang%20B%20Zhu%20N%20Bi%20276%20Y%20Ma%20X%20Zhan%20F%20Wang%20L%20Hu%20T%20Zhou%20H%20Hu%20Z%20Zhou%20W%20Zhao%20L%20Chen%20J%20Meng%20Y%20277%20Wang%20J%20Lin%20Y%20Yuan%20J%20Xie%20Z%20Ma%20J%20Liu%20WJ%20Wang%20D%20Xu%20W%20Holmes%20EC%20Gao%20278%20GF%20Wu%20G%20Chen%20W%20Shi%20W%20Tan%20W%202020%20Genomic%20characterisation%20and%20epidemiology%20279%20of%202019%20novel%20coronavirus%20implications%20for%20virus%20origins%20and%20receptor%20binding%20Lancet"
        },
        {
            "id": "Organization_January_a",
            "alt_id": "23",
            "entry": "Organization, W.H., 2020. Surveillance case definitions for human infection with novel 281 coronavirus (nCoV): interim guidance v1, January 2020., in: Organization, W.H. (Ed.). World 282 Health Organization, Geneva.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Organization%2C%20W.%20H.%2C%202020%20Surveillance%20case%20definitions%20for%20human%20infection%20with%20novel%20281%20coronavirus%20%28nCoV%29%3A%20interim%20guidance%20v1%20January"
        },
        {
            "id": "Perlman_2020_a",
            "alt_id": "24",
            "entry": "Perlman, S., 2020. Another Decade, Another Coronavirus. New England Journal of Medicine.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Perlman%2C%20S.%2C%202020%20Another%20Decade%2C%20Another%20Coronavirus%202020",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Perlman%2C%20S.%2C%202020%20Another%20Decade%2C%20Another%20Coronavirus%202020",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Perlman%2C%20S.%2C%202020%20Another%20Decade%2C%20Another%20Coronavirus%202020"
        },
        {
            "id": "Purcell_et+al_2007_a",
            "alt_id": "25",
            "entry": "Purcell, A.W., McCluskey, J., Rossjohn, J., 2007. More than one reason to rethink the use of 285 peptides in vaccine design. Nat Rev Drug Discov 6, 404-414.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Purcell%2C%20A.W.%20McCluskey%2C%20J.%20Rossjohn%2C%20J.%20More%20than%20one%20reason%20to%20rethink%20the%20use%20of%20285%20peptides%20in%20vaccine%20design%202007",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Purcell%2C%20A.W.%20McCluskey%2C%20J.%20Rossjohn%2C%20J.%20More%20than%20one%20reason%20to%20rethink%20the%20use%20of%20285%20peptides%20in%20vaccine%20design%202007",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Purcell%2C%20A.W.%20McCluskey%2C%20J.%20Rossjohn%2C%20J.%20More%20than%20one%20reason%20to%20rethink%20the%20use%20of%20285%20peptides%20in%20vaccine%20design%202007"
        },
        {
            "id": "286",
            "alt_id": "Saif_1993_a",
            "entry": "286 Saif, L.J., 1993. Coronavirus Immunogens. Vet Microbiol 37, 285-297.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Saif%2C%20L.J.%20Coronavirus%20Immunogens%201993",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Saif%2C%20L.J.%20Coronavirus%20Immunogens%201993",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Saif%2C%20L.J.%20Coronavirus%20Immunogens%201993"
        },
        {
            "id": "287",
            "alt_id": "Sesardic_1993_a",
            "entry": "287 Sesardic, D., 1993. Synthetic peptide vaccines. Journal of medical microbiology 39, 241-242.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Sesardic%2C%20D.%20Synthetic%20peptide%20vaccines%201993",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Sesardic%2C%20D.%20Synthetic%20peptide%20vaccines%201993",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Sesardic%2C%20D.%20Synthetic%20peptide%20vaccines%201993"
        },
        {
            "id": "288",
            "alt_id": "Skwarczynski_2016_a",
            "entry": "288 Skwarczynski, M., Toth, I., 2016. Peptide-based synthetic vaccines. Chemical science 7, 289 842-854.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Skwarczynski%2C%20M.%20Toth%2C%20I.%20Peptide-based%20synthetic%20vaccines%202016",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Skwarczynski%2C%20M.%20Toth%2C%20I.%20Peptide-based%20synthetic%20vaccines%202016",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Skwarczynski%2C%20M.%20Toth%2C%20I.%20Peptide-based%20synthetic%20vaccines%202016"
        },
        {
            "id": "290",
            "alt_id": "Tian_et+al_2020_a",
            "entry": "290 Tian, X., Li, C., Huang, A., Xia, S., Lu, S., Shi, Z., Lu, L., Jiang, S., Yang, Z., Wu, Y., 2020.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Tian%20X%20Li%20C%20Huang%20A%20Xia%20S%20Lu%20S%20Shi%20Z%20Lu%20L%20Jiang%20S%20Yang%20Z%20Wu%20Y%202020"
        },
        {
            "id": "291",
            "alt_id": "291_2019_c",
            "entry": "291 Potent binding of 2019 novel coronavirus spike protein by a SARS coronavirus-specific human 292 monoclonal antibody. bioRxiv.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Potent%20binding%20of%202019%20novel%20coronavirus%20spike%20protein%20by%20a%20SARS%20coronavirusspecific%20human%20292%20monoclonal%20antibody%20bioRxiv"
        },
        {
            "id": "293",
            "alt_id": "Vita_2015_a",
            "entry": "293 Vita, R., Overton, J.A., Greenbaum, J.A., Ponomarenko, J., Clark, J.D., Cantrell, J.R., Wheeler, 294 D.K., Gabbard, J.L., Hix, D., Sette, A., 2015. The immune epitope database (IEDB) 3.0.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Vita%20R%20Overton%20JA%20Greenbaum%20JA%20Ponomarenko%20J%20Clark%20JD%20Cantrell%20JR%20Wheeler%20294%20DK%20Gabbard%20JL%20Hix%20D%20Sette%20A%202015%20The%20immune%20epitope%20database%20IEDB%2030"
        },
        {
            "id": "296",
            "alt_id": "Waterhouse_et+al_2018_a",
            "entry": "296 Waterhouse, A., Bertoni, M., Bienert, S., Studer, G., Tauriello, G., Gumienny, R., Heer, F.T., 297 de Beer, T.A.P., Rempfer, C., Bordoli, L., Lepore, R., Schwede, T., 2018. SWISS-MODEL: 298 homology modelling of protein structures and complexes. Nucleic Acids Res 46, W296-W303.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Waterhouse%2C%20A.%20Bertoni%2C%20M.%20Bienert%2C%20S.%20Studer%2C%20G.%20homology%20modelling%20of%20protein%20structures%20and%20complexes%202018",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Waterhouse%2C%20A.%20Bertoni%2C%20M.%20Bienert%2C%20S.%20Studer%2C%20G.%20homology%20modelling%20of%20protein%20structures%20and%20complexes%202018",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Waterhouse%2C%20A.%20Bertoni%2C%20M.%20Bienert%2C%20S.%20Studer%2C%20G.%20homology%20modelling%20of%20protein%20structures%20and%20complexes%202018"
        },
        {
            "id": "299",
            "alt_id": "Wrapp_2019_a",
            "entry": "299 Wrapp, D., Wang, N., Corbett, K.S., Goldsmith, J.A., Hsieh, C.-L., Abiona, O., Graham, B.S., 300 McLellan, J.S., 2020. Cryo-EM Structure of the 2019-nCoV Spike in the Prefusion 301 Conformation. bioRxiv, 2020.2002.2011.944462.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Wrapp%20D%20Wang%20N%20Corbett%20KS%20Goldsmith%20JA%20Hsieh%20CL%20Abiona%20O%20Graham%20BS%20300%20McLellan%20JS%202020%20CryoEM%20Structure%20of%20the%202019nCoV%20Spike%20in%20the%20Prefusion%20301%20Conformation%20bioRxiv%20202020022011944462",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Wrapp%20D%20Wang%20N%20Corbett%20KS%20Goldsmith%20JA%20Hsieh%20CL%20Abiona%20O%20Graham%20BS%20300%20McLellan%20JS%202020%20CryoEM%20Structure%20of%20the%202019nCoV%20Spike%20in%20the%20Prefusion%20301%20Conformation%20bioRxiv%20202020022011944462",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Wrapp%20D%20Wang%20N%20Corbett%20KS%20Goldsmith%20JA%20Hsieh%20CL%20Abiona%20O%20Graham%20BS%20300%20McLellan%20JS%202020%20CryoEM%20Structure%20of%20the%202019nCoV%20Spike%20in%20the%20Prefusion%20301%20Conformation%20bioRxiv%20202020022011944462"
        },
        {
            "id": "302",
            "alt_id": "Xu_et+al_2018_a",
            "entry": "302 Xu, X., Yan, C., Zou, X., 2018. MDockPeP: An ab-initio protein-peptide docking server. Journal 303 of computational chemistry 39, 2409-2413.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Xu%2C%20X.%20Yan%2C%20C.%20Zou%2C%20X.%20MDockPeP%3A%20An%20ab-initio%20protein-peptide%20docking%20server%202018",
            "oa_query": "https://sandbox-api.scholarcy.com/oa_version?query=Xu%2C%20X.%20Yan%2C%20C.%20Zou%2C%20X.%20MDockPeP%3A%20An%20ab-initio%20protein-peptide%20docking%20server%202018",
            "scite": "https://sandbox-api.scholarcy.com/scite_url?query=Xu%2C%20X.%20Yan%2C%20C.%20Zou%2C%20X.%20MDockPeP%3A%20An%20ab-initio%20protein-peptide%20docking%20server%202018"
        },
        {
            "id": "Zhao_et+al_2020_a",
            "alt_id": "35",
            "entry": "Zhao, Y., Zhao, Z., Wang, Y., Zhou, Y., Ma, Y., Zuo, W., 2020. Single-cell RNA expression 305 profiling of ACE2, the putative receptor of Wuhan 2019-nCov. bioRxiv.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zhao%20Y%20Zhao%20Z%20Wang%20Y%20Zhou%20Y%20Ma%20Y%20Zuo%20W%202020%20Singlecell%20RNA%20expression%20305%20profiling%20of%20ACE2%20the%20putative%20receptor%20of%20Wuhan%202019nCov%20bioRxiv"
        },
        {
            "id": "Zhou_0000_a",
            "alt_id": "36",
            "entry": "Zhou, P., Yang, X.-L., Wang, X.-G., Hu, B., Zhang, L., Zhang, W., Si, H.-R., Zhu, Y., Li, B., 307 Huang, C.-L., 2020. Discovery of a novel coronavirus associated with the recent pneumonia 308 outbreak in humans and its potential bat origin. bioRxiv.",
            "scholar_url": "https://scholar.google.co.uk/scholar?q=Zhou%20P%20Yang%20XL%20Wang%20XG%20Hu%20B%20Zhang%20L%20Zhang%20W%20Si%20HR%20Zhu%20Y%20Li%20B%20307%20Huang%20CL%202020%20Discovery%20of%20a%20novel%20coronavirus%20associated%20with%20the%20recent%20pneumonia%20308%20outbreak%20in%20humans%20and%20its%20potential%20bat%20origin%20bioRxiv"
        }
    ],
    "facts": [
        "a desperate need for vaccines to combat the epidemic of SARS-CoV-2",
        "an in silico approach based on the available virus genome to identify the antigenic",
        "which with higher potential immunogenicity were used for vaccine design",
        "most prevalent HLA alleles accounting for ~99% of Chinese population",
        "in vivo experiments are required to validate the effectiveness of these peptide vaccine",
        "China has become the center of an outbreak of viral lung infections caused by a new type",
        "SARS-CoV-2.The outbreak has so far infected over 74000 patients",
        "control measures have been relying on the rapid detection and isolation of symptomatic cases",
        "The genome sequence of SARS-CoV-2 isolate Wuhan-Hu-1 was retrieved from the NCBI database under the accession number MN908947",
        "Gene and protein sequences were acquired according to the annotation",
        "The online tool in IEDB was used for the analysis of the conserved regions",
        "effective. Immunogenic regions of antigenic epitopes of all proteins encoded by SARS-CoV-2 were screened to identify potential vaccine candidates",
        "in vivo trials are required to achieve the effectiveness of these vaccine peptides",
        "Immunogenic regions of antigenic epitopes of all proteins encoded by SARS-CoV-2 were screened to identify potential vaccine candidates"
    ],
    "claims": [],
    "findings": [],
    "processes": [],
    "key_statements": [
        "Immunogenic regions of antigenic epitopes of all proteins encoded by SARS-CoV-2 were screened to identify potential vaccine candidates"
    ],
    "top_statements": [
        "Since December 2019, Wuhan City, Hubei Province, China has become the center of an outbreak of viral lung infections caused by a new type of coronavirus, SARS-CoV-2 (<a class=\"ref-link\" id=\"cGorbalenya_2020_a\" href=\"#rGorbalenya_2020_a\">Gorbalenya, 2020</a>; Joseph T Wu*, 2020; Organization, 2020; <a class=\"ref-link\" id=\"cPerlman_2020_a\" href=\"#rPerlman_2020_a\">Perlman, 2020</a>).The outbreak has so far infected over 74000 patients, and has spread to approximately 30 countries/regions worldwide",
        "Immunogenic regions of antigenic epitopes of all proteins encoded by SARS-CoV-2 were screened to identify potential vaccine candidates"
    ],
    "headline": "Immunogenic regions of antigenic epitopes of all proteins encoded by SARS-CoV-2 were screened to identify potential vaccine candidates",
    "contexts": [],
    "abbreviations": {
        "NCIP": "novel coronavirus-infected pneumonia",
        "COVID19": "coronavirus disease 2019",
        "RBD": "receptor binding domain",
        "ACE2": "angiotensin-converting enzyme 2"
    }
}
